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Patients with Type 1 diabetes (T1D) may develop a wide variety of additional
slowly progressing complications, which have been shown to be partly heritable
and to correlate with each other. However, the genetic and biological mechanisms
behind them are still mostly unknown. The goal of this work was to use machine
learning and data mining approaches that could capture the progressive nature
of multiple complications simultaneously, and create novel phenotype classes that
could help to solve the pathogenesis and genetics of diabetic complications.
To achieve this, a dual-layer self-organizing map (SOM) was trained using clinical
and environmental patient data from the FinnDiane study, and the trained SOM
node prototypes were clustered to classes using agglomerative hierarchical clustering.
The genetic differences between the created classes were evaluated using heritability
estimates, and the genetic markers associated with the class assignments showing
significant heritability were analysed in genome-wide association study (GWAS).
The created class assignments were biologically plausible, and were estimated to
be up to 42% genetically determined. The GWAS analyses detected a genetic
marker (rs202095311, located in the last intron of the gene NRIP1 ) genome-wide
significantly (p < 5×10−8) associated with one of the created class assignments. In
addition, GWAS detected multiple other genetic regions with suggestive p-values
that contained mostly genes and processes previously linked to diabetic complica-
tions or their risk factors.
Overall, the new approach to study the genetics of complex diseases was found to
perform well in case of T1D and its complications, and could be used to study also
other complex traits and diseases.
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Tyypin 1 diabetikoille saattaa kehittyä useita hitaasti eteneviä lisäsairauksia, jotka
ovat osittain perinnöllisiä sekä keskenään korreloivia. Sekä geneettiset että biologiset
mekanismit näiden taustalla ovat kuitenkin pääasiassa vielä tuntemattomia. Tämän
työn tarkoituksena oli hyödyntää koneoppimis- ja tiedonlouhintamenetelmiä, joiden
avulla pystyttäisiin vangitsemaan samanaikaisesti useiden diabeettisten komplikaa-
tioden etenevä luonne, sekä muodostamaan uusia fenotyyppiluokkia diabeettisten
komplikaatioiden ja niiden genetiikan tutkimuksen avuksi.
Työssä opetettiin monitasoinen itseorganisoituva kartta (SOM) käyttäen FinnDiane
tutimuksessa kliinisistä muuttujista sekä ympäristötekijöistä kerättyä potilasdataa.
Uusien fenotyyppiluokkien luomiseksi opetetun kartan prototyyppialkiot kluste-
roitiin kokoavalla hierarkkisella klusteroinnilla. Luokkien välisiä geneettisiä eroja
vertailtiin heritabiliteettiestimaateilla. Lisäksi luokkajakoon assosioituvien geneet-
tisten markkereiden vaikutusta tutkittiin perimänlaajuisessa assosiaatiotutkimuk-
sessa (GWAS) niiden luokkien välillä, jotka saavuttivat merkitseviä estimaatteja
heritabiliteeteille.
Muodostetut potilasluokat olivat biologisesti mielekkäitä ja muodostetun luok-
kajaon estimoitiin olevan jopa 42% geneettisesti määräytyvä. Perimänlaajuisissa
assosiaatiotutkimuksissa geneettinen variantti (rs202095311 NRIP1 geenin viimei-
sessä intronissa) assosioitui yhteen muodostetuista luokkajaoista genominlaajuisella
merkitsevyystasolla (p < 5 × 10−8). Lisäksi analyyseissa havaittiin viitteellisillä
p-arvoilla useita muita geneettisiä alueita, joilla sijaitsee aiemmin diabeettisiin
komplikaatioihin tai niiden riskitekijöihin yhdistettyjä geenejä ja prosesseja.
Yleisesti, uusi lähestymistapa kompleksisten sairauksien genetiikan tutkimukseen
suoriutui sille asetetuista haasteista tyypin 1 diabeteksen ja sen komplikaatioiden
tutkimuksessa ja vastaava lähestymistapa voisi olla hyödynnettävissä myös muiden
kompleksisten sairauksien tutkimuksessa.
Avainsanat: tyypin 1 diabeteksen komplikaatiot, FinnDiane, monitasoinen itse-
organisoituva kartta, klusterointi, heritabiliteetti, perimänlaajuinen
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Symbols and abbreviations
Symbols and Operators
Rd d-dimensional real-valued coordinate space∑
Sum over elements
argmin
i
Index i of element minimizing the argument
|  | Cardinality, "number of elements in a set"
||  || Euclidean norm
bc Floor function, rounding down to nearest integer
O() Big O notation, "the complexity is dominated by the function"
Abbreviations
2-AG 2-arachidonoyl glycerol
AC Agglomerative coefficient
ACR Albumin-to-creatinine ratio
AER Albumin excretion rate
AGE Advanced glycation end-products
AHT Antihypertensive (medication)
AMI Acute myocardial infarction
ApoA-I Apolipoprotein A-I
ApoB Apolipoprotein B
bp Base pair (nucleotides in DNA)
BL Baseline, refers to data measures obtained from patients at the
time when they entered the study
BMU Best matching unit
CAD Coronary artery disease
CHD Coronary heart disease
chr Chromosome
CVD Cardiovascular disease
DAG Diacylglycerol
DBP Diastolic blood pressure
DN Diabetic nephropathy
DPN Diabetic polyneuropathy
DR Diabetic retinopathy
EDNSG European Diabetic Nephropathy Study Group
ESRD End-stage renal disease, the most severe form of diabetic
nephropathy
FinnDiane Finnish Diabetic Nephropathy (Study)
viii
FU Follow-up, refers to data measures obtained from patients at the
second visit during the study
GCTA Genome-wide Complex Trait Analysis (software)
GRM Genetic relationship matrix
GWAS Genome-wide association study
HbA1c Glycoted haemoglobin A1c
HDL High-density lipoprotein
IHD Ischemic heart disease
IMT Intima media thickness
IQR Interquartile range
kb Kilobases, genetic distance of 1,000 nucleotide base pairs
LADA Latent autoimmune diabetes of the adult
LD Linkage disequilibrium
MAF Minor allele frequency
MAP Mean arterial pressure
MATLAB Matrix Laboratory, computational software and programming
language by MathWorks
MODY Maturity onset diabetes of the young
OR Odds ratio
PC Principal component
PDR Proliferative diabetic retinopathy
PKC Protein kinase C
PVD Peripheral vascular disease
QC Quality control
QE Quantization error of SOM
QQ-plot Quantile-quantile plot
REML Restricted maximum likelihood (analysis)
ROS Reactive oxygen species
SBP Systolic blood pressure
SE Standard error
SNP Single-nucleotide polymorphism
SOM Self-organizing map
T1D Type 1 diabetes
T2D Type 2 diabetes
TG Triglyceride
TE Topographical error of SOM
V-ATPase Vacuolar-type H+-ATPase
WHR Waist-to-hip ratio
1 Introduction
Finland has the largest prevalence of type 1 diabetes (T1D) in the world [1], and
the incidence of T1D is steadily increasing both in Finland and worldwide [2, 3].
The diagnosis of T1D is usually followed by a variety of different complications in
the following years, and these complications are the major cause of the decrease
in life quality and increase in premature mortality observed in diabetes. Whereas
complication-free patients with T1D have the same life expectancy compared with
their non-diabetic peers, for example the T1D patients with end-stage renal disease
(ESRD) have an 18-fold risk of dying early [4]. However, the most common cause
of death for patients with T1D is not nephropathy itself, but cardiovascular disease
(CVD) [5]. At the same time diabetic retinopathy (DR) is the leading cause of
acquired visual disability among people of working age in all industrialized countries
[6].
The development and progression of diabetic complications is not fully understood
but many clinical and environmental risk factors have been identified for these traits.
It seems that some of the complications share common risk factors, mechanisms
and pathways and many of the clinical phenotypes correlate with each other. For
example almost all patients developing diabetic nephropathy (DN), a complication
affecting the kidneys, have also complications of DR.
Many of the complications of T1D have been shown to be partly heritable [7, 8, 9],
however, only few genetic markers affecting them have been found regardless of
large efforts [10, 11, 12]. This might be partly due to the dependencies between
different complications, cluttering the analyses focusing only on one trait at a time.
Our previous studies have shown that some of the genetic associations can only
be detected in smaller subsets of patients within a certain trait, for example we
have identified a genetic marker affecting the risk of ESRD in women, but not in
men [13]. Similarly, analysing a set of extreme patients having both ESRD and
severe DR amplified the strength of genetic associations compared with analysing the
complications separately (regardless of the smaller patient sample) [14]. Thus there
is a need for new approaches that take into account multiple traits simultaneously, if
we want to identify the genetic components affecting diabetic complications.
Due to recent advancements in computer sciences, the amounts of stored data
and the computational power are increasing at an exploding rate. New tools in fields
of data mining and machine learning are necessary in order to handle and process
these massive datasets. These tools are able to extract the important and relevant
information among all the data available. Most of us encounter these tools almost
daily without even noticing it. They are the base for example in the search engines
and make it possible for Google to find the internet page of your interest using only
a couple of search terms, or in marketing when the YouTube video you are watching
is interrupted by an advertisement of an item of your interest.
This rapid increase in available data applies also to medical sciences, and the goals
in them are generally not so different from the examples above; to use the patterns
in vast data available to find an important phenomena, and further transform this
information into something concrete for the people. Instead of providing the user
2with a desired internet page, the ultimate goal in medical sciences could be for
example better care for the patients affected by a disease, or even medicine and cure
for it. However, the basic principle is the same: to go from data to knowledge and
even beyond. Thus the idea of applying these machine learning and data mining
approaches also in medical sciences seems generally appealing.
The traditional analyses used to solve the genetics of the diabetic complications
have shown thus far only small success, possibly due to the slowly progressing nature
of the complications and/or the limited number of patients that have been included
in the studies. The role of this work is to try alternative approaches that could tackle
these limitations and move the study of diabetic complications and their genetics
forward using machine learning approaches on the massive amounts of data already
available.
1.1 Aims of the study
This work combines multiple methods from the areas of machine learning, data
mining and statistics with a goal to create novel phenotype classifications for patients
with T1D. The created classes are further evaluated by comparing their genetic
background. The goal is to find the markers having an effect on the profile differences,
which can be used to better understand the pathogenesis of the diabetic complications.
These new approaches are needed in order to capture the progressive nature of the
diabetic complications and to find the associations that might be missed by traditional
approaches studying only one of the complications at a time.
The specific aims of this study are:
1. Create novel phenotype classes of patients with Type 1 diabetes by clustering
the prototypes of a multi-layer SOM, which has been trained using clinical and
environmental patient data.
2. Evaluate whether the created classes show genetically divergent background
and find the genetic variants associated with this class assignment.
In order to achieve these goals, first a multi-layer SOM is trained using data from
the Finnish Diabetic Nephropathy (FinnDiane) Study that contains thousands of
patients with T1D and hundreds of variables describing them. The multi-layer SOM
is trained using measures from different time points in different layers in order to
capture the progressive nature of the diabetic complications, which can easily be
missed with traditional approaches. After this, multiple different clustering methods
are applied to classify the trained SOM prototypes in order to find the method that
is most suitable for the task of creating novel phenotype profiles.
Finally the most suitable clustering method is applied to create the novel pheno-
type classes by clustering the SOM prototypes into differing number of clusters. When
the number of clusters is increased, more specified patient subtypes can be identified.
As a proof of concept, these groups are evaluated by intergroup heritabilities to
detect the classes that have genetically divergent background. Ultimately, millions
of genetic markers are tested for their association with these group assignments in a
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Figure 1: General overview of the analysis pipeline. Refer to sections 3 and 4 for
more detailed information.
genome-wide association study (GWAS) setting to pinpoint the genetic component
creating the differences in complication prevalence and/or rate of progression to the
next level. The general overview of the analysis pipeline is presented in Figure 1.
On top of this potentially clinically important information, also the method-
ologically interesting questions are addressed. The secondary goals of this work
are:
1. Evaluate whether the multi-layer SOM is able to capture the progressive aspect
of the diabetic complications.
2. Evaluate which of the clustering methods is the most suitable to create the novel
phenotype classifications, when combined with the multi-layer SOM approach.
3. Evaluate the performance of the approach as whole, and whether similar pipeline
could be used to study the genetics of other progressive complex diseases.
42 Physiology of diabetes
Diabetes is a general class of metabolic disorders, which are all characterized by
elevated blood glucose concentrations. The rise in blood glucose levels can be caused
by a decreased secretion of insulin by pancreatic β-cells, an impaired effect of insulin
in target tissues or by combination of both. On top of affecting the carbohydrate
metabolism, diabetes also disturbs the normal lipid and protein metabolism of the
body.
Diabetes can be roughly categorized into two major forms, type 1 diabetes (T1D)
and type 2 diabetes (T2D), even though the distinction between the two is not
always straightforward and usually patients have features of both types. In T1D an
autoimmune reaction destroys the pancreatic β-cells in the insulin secreting islets
of Langerhans, and results in complete insulin deficiency. It usually occurs at a
young age (less than 35 years), and requires a lifelong insulin therapy. T2D is mainly
caused by decreased insulin sensitivity and/or decreased insulin secretion, and it is
usually prevalent in older age groups (over 40 years) or in the presence of obesity. In
addition, there exist rarer subtypes of diabetes: latent autoimmune diabetes of the
adult (LADA) which is autoimmune in origin as T1D, but clinically resembles T2D;
maturity onset diabetes of the young (MODY), which is a class of highly prevalent
monogenic diabetes; and gestational diabetes, which occurs during pregnancy. This
work concentrates on T1D, and later when the term diabetes is used, it refers to
T1D if not otherwise specified.
T1D requires a lifelong insulin therapy, where the patients are required to monitor
their blood glucose levels and inject insulin accordingly to keep it stable. A modern
insulin therapy consists of multiple daily injections, or continuous subcutaneous
insulin infusion using an insulin pump. In the more common form of the therapy
where the insulin injections are used, a long-lasting basal insulin is injected once or
twice a day accompanied by additional rapid acting insulin bolus injections during the
mealtimes. In pump therapy, a rapid acting insulin is administered with a constant
rate with addition of patient-activated bolus doses during the mealtimes. The amount
of insulin in the boluses (both in pump therapy and when using multiple daily insulin
injections) has to be determined separately each time based on the pre-meal glucose
levels of the patient and the carbohydrate content of the meal. The insulin dose
also need to be adjusted according to daily factors such as diet and physical activity
as well as patient-dependent factors such as insulin sensitivity, stress, and pubertal
status. The monitoring of glucose levels and determining the suitable insulin doses
are the responsibility of the patients themselves creating an additional burden to the
daily activities.
Keeping the blood glucose on a suitable and stable level is important as the
glycaemic control is one of the most important risk factors for the development
of long-term diabetic complications as later discussed in section 2.2. In addition,
too high or too low glucose levels can also cause acute symptoms. When the
glucose levels rise to a high level, i.e. during acute hyperglycaemia, the normal
body metabolism is disturbed. The first signs include for example thirst, hunger,
increased urinary volume, sleepiness, and blurred vision. If the condition is left
5untreated it can lead to a state called diabetic ketoacidosis, where the body starts to
burn fatty acids resulting in acidic ketone bodies. Ketoacidosis will further cause
symptoms such as deep rapid breathing, confusion, decreased level of consciousness
and impaired cognitive function. Ketoacidosis is a medical emergency and requires
hospital treatment. If the ketoasidosis is left untreated it can result in coma or
even the death of the patient. Correspondingly, hypoglycaemia, i.e. too low blood
glucose level, cause acute symptoms which typically occur more rapidly compared
with hyperglycaemia. This state can occur if the patient takes too much insulin
decreasing the blood glucose to too low levels. First the body releases natural
counter-regulatory hormones (adrenaline and glucagon) which cause symptoms such
as anxiety, nervousness, stronger and faster heart beat, sweating, nausea, vomiting
and headache. These hormones can postpone the drop in the blood glucose for
a while, however, the lack of glucose will soon start to affect the brain. At this
point additional symptoms may occur including impaired judgement, irritation and
mood changes, confusion, dizziness, blurred vision, flashes of light in the field of
vision, difficulty of speaking, temporal paralysis and seizures. As in the case of
hyperglycaemia, in the extreme cases also hypoglycaemia will result in coma and
in the worst case the death of the patient. As the symptoms of impaired glucose
management are so severe, monitoring and keeping the blood glucose levels stable
may cause an unnecessary fear and additional stress to some patients with T1D.
Some of the patients with T1D may also develop long-term diabetic complications
that take years to appear. Next in section 2.1 the most common of these are
introduced after which section 2.2 will go through the known risk factors affecting
these traits.
2.1 Diabetic complications
Although diabetes can be managed by modern insulin therapy and by monitoring
of blood glucose levels, the treatment cannot fully mimic the human pancreas and
return the body metabolism to normal. This is evident as a subset of patients with
diabetes develop a wide variety of long-term diabetic complications [15]. These
complications are the major causes of premature mortality and decrease in the life
quality [4]. The most common long-term diabetic complications can roughly be
divided into micro- and macrovascular complications.
The microvascular complications are the result of cellular damage in the small
blood vessels and tissues surrounding them. The most common of these is diabetic
retinopathy (DR) [16], where the vessels in the retina of the eye get weaker and might
leak to the surrounding tissues. If advanced, the small arteries become stiffer and
new abnormal weak blood vessels start to grow around the damaged areas in response
to ischemia. This advanced form of DR is called proliferative diabetic retinopathy
(PDR). Usually the first signs of DR are harmless, but even the smallest changes
can affect the patients vision and in the worst case DR can lead to total blindness.
In fact, DR is the leading cause of blindness in the working age population in the
western world [6]. Still, almost all of the patients with T1D will get some degree of
DR during their lifetime [17]. Another microvascular complication affecting many
6patients with diabetes is diabetic (poly)neuropathy (DPN), a heterogeneous class
of microvascular complications affecting the nerves of the patient. It is thought to
result from injury in the small blood vessels supplying the nerves. It may affect all
peripheral nerves including pain fibres, motor neurons and the autonomic nervous
system. Different forms of DPN can cause for example unpleasant sensory symptoms
such as pain, numbness, burning sensation or tingling as well as exercise intolerance,
diarrhoea, erectile dysfunction and loss of bladder control to name few of the possible
symptoms.
While these two complications are mainly not life threatening and cause mainly
symptoms decreasing the life quality, the third microvascular complication, diabetic
nephropathy (DN), makes an exception. The small vessels in the kidney form special
structures, nephrons, that are responsible for the filtration of the waste products
from blood to urine and the overall fluid balance of the body. In DN, when these
microvascular structures are damaged, the filtration rate of the kidney gets worse,
and the substances that should not be filtered from the blood start to leak to the
urine through the kidneys. In order to confirm DN, an invasive kidney biopsy and
histological studies would be required, however, DN is clinically diagnosed in Finland
and around the Europe by measuring the protein (albumin) levels of the urine and
classified into three groups based on the level: normal albumin excretion rate (AER),
microalbuminuria and macroalbuminuria. The fourth and the most severe stage,
end-stage renal disease (ESRD), is referred to when the kidney function is lost to a
level where a regular dialysis treatment or a kidney transplantation is required for the
survival of the patient. Whereas the early symptoms of DN might be undetectable
for the patient, it is a significant risk factor for increased mortality in T1D. In the
absence of DN, the long-term survival rates of patients with T1D do not differ from
the general background population without diabetes, but patients with ESRD have
an 18-fold risk of the premature death [4].
All of the microvascular complications share common pathogenetic mechanisms,
pathways and risk factors and they are strongly associated with each other. They are
all slowly progressing diseases and take usually years to develop. After the duration of
15 years almost all patients have at least the first signs of DR [18], and approximately
half of the patients have DPN after 15 to 20 years of diabetes [19]. The largest
increase in incidence of PDR is seen after 10 years of diabetes [20], whereas in DN
the peak incidence occurs after 15 to 20 years of diabetes, after which approximately
one third of the patients have signs of DN [21].
The second large group of complications, macrovascular complications, can
be divided into different subclasses of cardiovascular diseases (CVD): coronary
artery disease/coronary heart disease/ischemic heart disease (CAD/CHD/IHD),
stroke/cerebrovascular disease, and peripheral vascular disease (PVD). They are
all caused by atherosclerosis in the large blood vessels, and the different disorders
are classified by the location of the damage (similarly as in diabetic microvascular
complications). CAD includes forms affecting the arteries supplying the heart, cere-
brovascular disease includes forms affecting the arteries supplying the brain and PVD
generally the lower limbs.
These macrovascular complications are common in patients with T1D, and the
7risk for developing them is much higher compared with the background population
without diabetes. It has been shown that the intima media thickness (IMT, a
surrogate marker for atherosclerosis) in patients with T1D is comparable to 20
years older peers without diabetes [22]. This is directly reflected in the risk of
CVD events and mortality. Patients with T1D have 10 to 15-fold increased risk of
lower-extremity amputation due to PVD compared with the background population
[23]. Correspondingly, the risk for stroke is reported to be approximately 18-fold
in men and 26-fold in women with T1D [24], and the risk for CHD mortality has
been reported to be 9-fold for men and over 40-fold for women [25], compared with
non-diabetic peers. Importantly, the incidence rate of CVD events in women with
T1D is comparable to the incidence rate in men with T1D, suggesting a loss of sex
specific protection seen in the background population. Thus the relative risks of CVD
events for women are much higher compared with men. Furthermore, the risk for
CVD events is highly correlated with the severity of DN [24], and this is notably seen
also in the all-cause mortality risk [4], as CVD events are the most common cause
of death in patients with T1D [5]. However, the causes for the strong association
between DN and CVD are still unknown.
In addition to the micro- and macrovascular complications, patients with T1D
are also more susceptible to other autoimmune diseases, when compared with the
background population without diabetes, such as autoimmune thyroid disease, coeliac
disease, multiple sclerosis, rheumatoid arthritis and asthma, as reviewed in [26].
Psychiatric disorders are also common including depression, anxiety, diabetes-related
stress, eating disorders and other mental health symptoms [26]. Additionally, patients
with T1D suffer from various other health related problems, for example they are
generally more susceptible to bacterial infections compared with the diabetes-free
background population [27].
2.2 Genetic and environmental risk factors of diabetic
complications
Many different risk factors, both environmental and genetic, have been identified for
the long-term diabetic complications. The environmental risk factors usually overlap
for many of the complications, as illustrated in Table 1, that summarises some of
the most common risk factors and their association with different complications.
Among these risk factors, glycaemic control can be considered the most important
for microvascular complications, as it affects multiple damaging biochemical path-
ways common for all of them. Hyperglycaemic conditions cause overproduction of
advanced glycation end-products (AGEs) and activation of the polyol, hexosamine
and diacylglycerol-protein kinase C pathways, which all have been associated with
microvascular damage [28, 29]. For these pathways, the overproduction of reac-
tive oxygen species (ROS) have been suggested as "the unifying mechanism" [29].
Glycaemic control affects also the risk for macrovascular complications, but other
markers such as the lipid profile, age and blood pressure have a larger effect on them.
On top of the glycaemic control also different time related variables (such as age,
diabetes duration and age at diabetes onset) as well as blood pressure, smoking and
8Table 1: Most common environmental risk factors for micro- and macrovascular
diabetic complications.
DN DR DPN CVD
Blood pressure ∗ ∗ ∗ ∗
Glycaemic control ∗ ∗ ∗ ∗
Insulin resistance ∗ ∗ ∗ ∗
Lipid profile ∗ (∗) ∗ ∗
Obesity (/WHR/BMI) ∗ ∗ ∗ ∗
Smoking ∗ ∗ ∗ ∗
Time related variables ∗ ∗ ∗ ∗
Anemia ∗ ∗
Gender ∗ ∗ ∗
Height ∗ ∗
Puberty ∗ ∗
Adiponectin ∗
Birth weight ∗
Heavy alcohol consumption ∗
High protein diet ∗
Inflammatory markers ∗
Pregnancy (∗∗)
Recent cataract surgery ∗
∗ = associated risk factor, (∗) = debated, (∗∗) = transient, long-term
risk not affected
lipid profile (to some degree) seem to be common for both micro- and macrovascular
complications. Additionally the different diabetic complications are considered as
risk factors for each other.
These environmental risk factors do not fully explain all the attributable risk for
any of these complications, suggesting the involvement of genetic risk factors. These
assumptions are also supported by studies showing familial clustering of many of these
complications [7, 8, 9]. However, despite large efforts only few genetic markers have
been found for them. Where environmental risk factors are more general affecting
many complications simultaneously, genetic factors are mainly found associated with
one of the complications at a time. However, there is also some studies showing
pleiotropic effects of certain markers [14].
Of the diabetic microvascular complications, DN is the most widely studied in
terms of genetics [12]. Multiple smaller candidate gene studies have been performed,
and the results have been combined in systematic meta-analysis. Mooyart et al.
reported multiple variants associated with DN based on this meta-analysis, located
near genes such as ACE, AKR1B1, APOC1, APOE, EPO, NOS3, VEGFA, CARS,
and GREM1 to name a few [30]. However, these associations are under debate, as the
level of significances did not reach genome-wide level even in the meta-analyses [12].
For DN, also large consortia-based GWAS analyses have been performed, which have
9yielded associations reaching the genome-wide significant threshold. Two variants
near the gene AFF3, and between genes RGMA and MCTP2 were associated with
ESRD, and a variant in an intronic region of ERRB4 was suggestively associated
with DN [10]. In addition, a marker that is associated with ESRD in women only
was found between the genes SP3 and CDCA7 [13].
For DR, multiple candidate gene studies showing associations to different genetic
markers have been performed, but the reported results have been mainly conflicting
(with a significance far away from the genome-wide level), possibly due to small
sample sizes and varying phenotype definitions. Of these, the genes AKR1B1, AGER,
VEGF/VEGFA, NOS3, and ACE are among the most studied [31, 32], but there are
also many other candidate regions tested and even GWASs performed, however, none
of which have yielded genome-wide significant associations [32]. Also systemic efforts
to replicate the previous DR associations in independent cohorts have been made
[11], however, they have not been able to confirm any of the associations affecting
the risk of DR.
Of microvascular complications, DPN has shown least results with genetic studies,
possibly because it is a more heterogeneous complication compared with DN and DR.
Until now there are no GWASs performed on DPN, and no genetic associations worth
mentioning have been found, excluding variants in the genes SCN9A and TRPA1,
which are found to be causal of certain monogenic neuropathic conditions [12].
The macrovascular complications have been widely studied in healthy populations
without diabetes, and the performed GWASs have been magnitude(s) larger compared
with the diabetes specific complications. For example, a GWAS of almost 200,000
patients was performed for CHD by CARDIoGRAMplusC4D Consortium, and after
their analyses the number of genetic loci reaching genome-wide significance for CHD
risk was increased to 46 [33]. However, as the risk for CVD events is clearly elevated
in diabetes, the interesting study question is whether there are diabetes specific
genetic markers affecting CVD, or is there an interaction between diabetes and known
genetic CVD risk markers. Such interactions have been found with different CVD
outcomes and T2D as reviewed by Ahlqvist et al. in [12], however, there is little if
any such results in patients with T1D.
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3 Computational methods
In this work multiple different methods from the areas of machine learning, data
mining and statistics are used to better understand the mechanisms behind diabetic
complications. In this section, the theoretical background of the most relevant
methods used in this work are discussed. First, section 3.1 presents the theory of
traditional and multi-layer SOM going through the algorithm and the properties of
this approach. Next, section 3.2 introduces the problem of clustering and the methods
used to group SOM prototypes together in order to create the novel phenotypes.
Finally, section 3.3 introduces the methods used to estimate the heritability and
genetic associations with the novel phenotypes.
3.1 Self-organizing map
The SOM is an unsupervised neural networks algorithm originally based on a model of
the nervous system and competitive learning. The algorithm was developed by Teuvo
Kohonen and introduced in the 1980s [34]. Briefly, the algorithm performs mapping
of high dimensional data to a low dimensional ordered grid (usually two-dimensional),
while preserving the most important local relationships between data points. While
effectively reducing the dimensionality of the data, allowing effective visualization,
the algorithm also creates abstractions of the data in form of model prototypes. Both
of these properties will be useful when studying large multidimensional datasets with
underlying hidden patterns.
In competitive learning, the basic principle is that neurons in neural network
adapt to the data in order to become sensitive for certain patterns. In the easiest
form, the neuron that best matches the presented input data "wins the competition"
and is allowed to learn and adapt closer to presented data. This same idea applies
also in SOM, but the speciality it introduces is the connections between these nodes.
Not only the winning node is learning, but also its neighbours close by are gaining
the information and adapting based on it.
The basis for SOM is a grid of nodes that have well defined spatial positions or
connections between them. Possibly the easiest form is a two dimensional regular
square lattice (see Figure 3 in section 3.1.1). The nodes and the spatial relations
(distances) are presented in a two-dimensional space R2, and each of these nodes have
an initial built-in prototype in the d-dimensional space Rd, where d is the number
of the features in the used training samples. In the SOM training algorithm, the
input data vectors (the training data) are presented to the adapting neural network
randomly one at the time. At every iteration step t, the node indexed with c whose
current prototype mc(t) is closest to the presented data vector x(t) (in Rd) among
all possible prototype vectors is selected as a winner of the round:
c = c(x(t)) = argmin
i
||x(t)−mi(t)||2. (1)
Generally the Euclidean distance is used, but other forms can be implemented as
well. After the winner is selected, all the node prototypes are moved closer to the
presented data vector (in Rd) according to the following rule:
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mi(t+ 1) =mi(t) + hc,i(t)(x(t)−mi(t)), (2)
where hc,i(t) is the neighbourhood function of the winning node. In basic formulation
[35, 36], it has a Gaussian form of:
hc,i(t) = α(t)exp
(
−||ri − rc||
2
2σ2(t)
)
, (3)
where 0 < α(t) < 1 is the learning-rate factor, which decreases monotonically with
the regression steps. ri ∈ R2 and rc ∈ R2 are the vectorial locations of the nodes in
the ordered two dimensional grid and σ(t) is the width of the neighbourhood function
which also decreases monotonically with the regression steps. In this form all the
nodes are adjusted, but the strength of the adjustment depends from their position
on the grid in relation to the winning unit. Only the winner itself is moved with the
factor of learning rate α(t), and all the other nodes are adjusted less. The immediate
neighbourhood will also be affected notably, but as the neighbourhood function
decreases rapidly as a function of the distance in the grid lattice, nodes far away
from the winner are left virtually unchanged. Also other forms of neighbourhood
function can be implemented, which are also used in practice. A simpler form of the
neighbourhood function can be implemented as follows:
hc,i(t) =
{
α(t), if ||ri − rc|| < r∗(t)
0, otherwise,
(4)
where r∗(t) is the monotonically decreasing radius, which defines the size of the
neighbourhood. In this form, the winning unit and the close by neighbours are all
moved towards the presented data vector with the same multiplier and nodes not
belonging to the neighbourhood set are left as is, as visualized in Figure 2. Regardless
of the form of the neighbourhood function, this iterative training is repeated for
a predetermined t times and the same data vectors are usually presented multiple
times to the SOM at different steps when the neighbourhood radius and learning
rate have decreased in order to achieve a large enough number of iterations [37].
In the beginning of the SOM training algorithm, when both the neighbourhood
radius and learning rate are at their maximum, the map is quickly changing and
adapting to the data as multiple nodes are moved at once relatively strongly towards
the presented data vectors. In this phase, the grid will quickly unfold and order
itself in the d-dimensional data space so that nearby units are in close segments
of the space matching the overall form of the training data cloud. As both the
neighbourhood radius and the learning rate decreases as the function of the iteration
steps, the nodes gradually start to stabilize and resemble the data vectors located
in close by regions. Usually (depending on the parameters) in the very end of the
training phase only the winning unit is moved at each iteration, thus, allowing the
fine tuning of the prototypes.
One of the advantages of the SOM algorithm, which makes it appealing to apply to
biological data, is that it can handle also data vectors with missing values during the
training. When a sample vector with missing values is presented, the winning node
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Figure 2: The adaptation of nodes during SOM training, visualized by using the
radial form of the neighbourhood function given in Equation (4). Picture from [38].
can be selected by computing the distances using only the subspace of non-missing
features of the presented data vector. If the proportion of missing elements is small,
the result will be "statistically fairly accurate". However, this assumption is no
longer valid when a majority of the features of the presented data vector are missing.
When updating the node prototypes using a vector with partly missing values, only
the dimensions present in the sample are to be altered [39].
After the SOM training phase the approach starts to really show its power when
the visualization and abstraction properties are taken advantage of. The positions of
the nodes stay unchanged in the two-dimensional grid during the training, but each
of them have learned a unique prototype that works as an abstraction describing
the data. Moreover, as these prototypes have adapted gradually together to their
final configuration and values, each of the node prototypes resemble quite closely the
neighbouring units. Thus the grid map will be full of local regions that share common
properties. If the nodes of the grid are coloured in the sense of a heat map according
to the values of the prototypes one feature (dimension) of the original data at a time,
one can detect that close by nodes share similar values and that the colouring (height
of the map) usually has a sub-continuous smooth surface. Based on these surfaces it
is possible to visually detect regions that have high/low values for certain interesting
features. Comparing multiple surfaces can help to find the features that have similar
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or contradicting patterns, which helps hypothesis generation and understanding of
the possible interplay between the features. Correspondingly, one might possibly
detect features that show close to no "heat patterns" in the grid, only a random
fluctuation, and thus, find variables that have close to no role in the organization of
the map. Furthermore, these prototypes can be used in clustering in order to find
classes within the data [40].
The trained SOM can be used to visualize the trained prototypes, but more
importantly, also new data vectors can be mapped to its units. This can be done
by computing the distances between the presented data vector and all the SOM
prototypes (in the feature space Rd), and mapping the new data to the node corre-
sponding to the closest prototype. These new vectors can be mapped to their best
matching unit (BMU) regardless of the possibly missing features, as the distance can
be minimized also in the subspace of the present features in the same way as when
training the SOM using data vectors with a missing values.
Even though being only one of the approaches among many provided by the
field of machine learning and data mining, the SOM gives promising attributes to
achieve the goals of this work. The multidimensional data with quite a lot of missing
values can be used to train the SOM and the resulting mapping can be used to gain
additional knowledge of the interplay between the measured variables. Furthermore,
the trained prototypes can be also clustered into novel phenotype classifications and
they can be further used to classify new patients.
3.1.1 Free parameters of SOM
When implementing a SOM, decisions regarding multiple free parameters are to be
made, regarding for example the size and form of the used grid, initialization of the
nodes, and the decay rates of the learning algorithm. There is no optimal decision
for any of these that would always outperform the others as the optimal parameters
are always problem dependent. Fortunately, there are multiple "rules of thumb" and
different methods to test the performance of the selected parameters to help the
researcher make these decisions.
The SOM topology, i.e. the shape and connections of node grid, can be in
principle selected arbitrarily, but there are two generally used topologies: a regular
square or a regular hexagonal lattice. In the square lattice, each of the nodes (expect
the ones in the very edges of the grid) have four neighbours connected to them.
Correspondingly, in the hexagonal topology each of the nodes are connected to six
neighbours. Advantages of these lattices are that they are regular and easy to visualize
in a two-dimensional plane, which makes the human interpretation of the maps easier.
However, these lattices have a set of special nodes which have less neighbours (the
nodes at the edges and corners of the map) that tend to have special properties.
Moving these nodes in the training iterations have less effect on the overall map (as
there are less neighbours) and more extreme values tend to locate into these edges
and corners of the SOM map. This phenomenon can be seen to occur by definition,
as similar nodes seek to move closer to each other making distant nodes dissimilar.
Therefore, the opposite edges and corners should be most distinct by definition and
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Figure 3: Different grid topologies used in SOM. From left, a regular square grid, a
regular square grid folded into a cylinder and a regular square clynider folded into a
torus. Figure editted from [38].
thus present the most extreme profiles of the data. An easy way of fixing this possibly
problem causing property is to connect the edges of the lattice, so that the topmost
nodes are connected as neighbours to the bottommost nodes, creating a cylinder. If
the leftmost nodes are further connected to the rightmost nodes, the grid creates a
torus. This way the grid can still be visualized in two-dimensional plane, but there
is no corners or edges that would have special properties and each of the nodes have
exactly the same number of neighbours and the same form of the neighbourhood.
These different grid topologies are presented in Figure 3.
Another free parameter of the SOM is the size of the used grid. Both the number
of nodes, and what is the proportion of height and width of the grid can be freely
chosen. However, both of these selections have impact on the SOM performance and
the selection is not straightforward to make. The number of nodes should not be too
small in order to avoid too general prototypes i.e. nodes being representative of too
many data vectors. Correspondingly, the number of nodes should not be too large, so
that the resulting prototypes indeed would summarize the close by data vectors, and
that there would not be too many empty nodes where no data vectors are mapped
at all. For similar reasons the height/width proportion of the grid should not be
too large or small. Multiple different methods to select these parameters have been
proposed, but there is no guarantee that any of these would yield better results than
the others. One of the methods to determine the grid size is based on the general
"rule of thumb", implemented for example in the SOM-toolbox for MATLAB [38].
By this rule the goal number of nodes in the SOM grid, m, is set at
m = 5
√
n, (5)
where n is the number of training samples. The ratio between side lengths is set
to be the ratio between the two largest eigenvalues of the covariance matrix of the
training data.
Also, the initial positions of the grid nodes in the data space Rd is one of the
free parameters to be selected. Generally for this, there are two different approaches:
a random initialization and a data analysis based initialization. The latter can be
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implemented based on a certain projection of the data, for example projection to
the subspace spanned by the top two eigenvectors. However, none of these methods
guarantee a better solution compared with the others [41].
Finally the shape and form of the neighbourhood function, its learning rates and
decaying parameters, as well as the number of training iterations are to be selected.
The neighbourhood function can in principle be of any form and arbitrarily selected,
however, the most used forms were introduced in chapter 3.1 in Equations (3) and
(4). The corresponding monotonically decreasing decay parameters including the
learning rate are usually implemented as linearly decreasing, exponential or inversely
proportional to the time, but the exact rule is not important [36]. The learning rate
can start from close to a unity and the neighbourhood should initially include a large
proportion of the nodes in order to allow the global ordering. Ultimately, the number
of iteration steps should be large enough to allow a good statistical accuracy, and
a value of "at least 500 times the number of network units" has been suggested by
Kohonen himself [36].
3.1.2 Multi-layer SOM
The basic model of the SOM can also be extended to contain multiple layers of
SOM grids that are trained simultaneously, using different datasets (for the same
samples) in each of the layers. These datasets can contain even a different number
of totally different features, as the training of the layers is done independently in
their own Rdj dimensional feature spaces. In principle, the only difference occurs
during the process where the index of the winning node, c, is selected during the
training. Whereas in a traditional single layer SOM the selection is made according
to the distance in d-dimensional space (see Equation (1)), in multi-layer SOM the
decision is made according to the sum of weighted distances throughout multiple
dj-dimensional spaces, each corresponding to one of the layers j and therefore one of
the datasets, i.e.
c = c(x(t)) = argmin
i
l∑
j=1
wj||xj(t)−mi,j(t)||2, (6)
where l is the number of layers, wj is the weight associated to layer j, xj(t) is the
data vector of presented input in the dataset corresponding to the layer j andmi,j(t)
is the current prototype of the i-th node in the j-th layer.
This selected node therefore describes best the presented data point "on average"
throughout the layers. To clarify, the grids in different layers are of the same size
and shape, and the nodes in the same positions corresponds to each other. At every
iteration, the selected winning node is the same in every layer, and that node is
moved closer to the presented data point (according to its position in each of the
dj-dimensional data spaces of the corresponding layer) in every layer individually
in the same fashion as in the single layer SOM. The weights of the layers can be
adjusted to give more importance to certain datasets, but the intuitive approach
is to set them all equal or corresponding to the number of features of the dataset
in the corresponding layer. In this study, both of these approaches would yield the
16
same outcome as the different layers used are of the same size corresponding to the
cross-sectional measures in the different time points.
The training data presented for the SOM needs to contain data for each of the
layers in order to train them. However, samples with totally missing data for a
certain layer can still be mapped back to the SOM after the prototypes are trained,
in a similar way as in the traditional single layer SOM the samples with missing
data can be mapped back to the grid. An implementation of the multi-layer SOM
described above can be found in the kohonen R package implemented as supersom
[42], which was used in the analyses of this work.
3.1.3 Evaluation of the SOM mapping
The form of the trained SOM is heavily affected by the selected free parameters, and
more importantly, it is random by definition as the training vectors are presented in
randomized order during the training iterations. Thus, different measures have been
developed to test whether the resulting mapping is good, which can later be used to
evaluate the outcome when the free parameters are tuned, or to select the best fit of
the SOM throughout different iterations.
Probably the most used measure is the quantization error (QE), which measures
how closely the trained prototypes resemble the actual data vectors. QE is defined
as the average distance between introduced sample vectors and their BMU of the
SOM prototypes in the feature space Rd. If the prototypes resemble the samples
very closely, the distance between the vector and its BMU in the feature space is
small. Controversially, if the trained prototypes end up presenting some arbitrary
subsection of the feature space, the distance for the mapped (relatively different)
samples can become large. Thus small QE will denote good mapping and larger ones
worse mapping.
A similar measure, describing the smoothness of the prototype grids, is called
topographical error (TE). If the mapping is smooth, the mapped samples should
be located approximately in between two adjacent prototypes, and thus the closest
prototype (BMU) and the second closest prototype should be connected in the SOM
grid. The basic form of TE computes the proportion of sample vectors, whose first
BMU and second BMU are not adjacent. The value for TE is limited to the interval
[0, 1], and smaller values denote smooth mapping and larger values poorer mapping.
However, this measure does not capture the whole picture, as it does not consider
how far the second BMU is located if it is not adjacent. Thus, this proportion based
TE can also be extended to distance based TE, where the error is defined as the
average distance (in the grid plane R2) between the first and second BMU of multiple
sample vectors. This measure will penalize the samples whose non-adjacent first and
second BMU are far away in the grid plane, but will suffer only small penalties if
they are still relatively close. The magnitude of the error is not limited to a certain
interval, but is dependent on the grid size. However, smaller values again denote
smoother mapping.
All three of these measures were used in this work when the performance of the
trained SOM was evaluated.
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3.2 Data clustering
Clustering is a general problem setting, where the goal is to divide the given data into
a (possibly unknown) number of groups, so that the elements within the same group
resemble each other more than the elements between different groups. The field of
clustering is very broad and there exists multiple different approaches to tackle the
problem. In this work the clustering is used to group the trained prototypes of the
multi-layer SOM into different classes that later can be used to classify the individual
patients accordingly.
The clustering approaches can be divided into classes by using multiple different
criteria. One methodological difference having a major impact on the clustering
problem at hand is the type of the input that the given method requires. Where
some of the clustering methods need the exact vector coordinates for the data points
to be grouped, some can manage using only the (dis)similarity matrix presenting the
relations between the data points.
As the multi-layer SOM prototypes to be clustered have position and coordinates
in multiple d-dimensional spaces, applying the basic implementations of most of the
clustering methods requiring the coordinate presentation of the data is not possible.
Some of these methods could also be hand tailored to suit the problem at hand, but
this is out of the scope of this work. There are also some workarounds to avoid this
problem, but they are not generalizable in all settings. Thus, if one wishes to expand
the pipeline of this work to other problems, diseases or traits, these workarounds
cannot necessarily be reasonably applied any more.
Luckily, the similarities between the multi-layer SOM prototypes are straight-
forward to determine, if one applies the same rules that are used when finding the
BMU in the training or mapping phase of the SOM as shown in the Equation (6).
Applying the same principle it is possible to determine the distance between any two
prototypes by computing the weighted average of euclidean distances throughout the
layers. Thus, it is easy to compute the distance matrix for all pairs of prototypes.
This distance matrix can be further negated to create a similarity matrix and either
of these is sufficient to perform the clustering using multiple different clustering
methods.
Therefore, this work concentrates only on the clustering methods that can be
applied to cluster the data based on the (dis)similarity matrix. Three different
methods were selected that all have well documented R implementation available.
The selected methods are widely used and/or have been shown to perform well when
applied on biological data before. The selected methods will be further introduced
in the following sections. First, in section 3.2.1 one of the the simplest forms of
clustering, the hierarchical agglomerative clustering, is introduced with the Ward’s
criteria for cluster merging. Next, section 3.2.2 introduces the concept of spectral
clustering, an approach which is based on clustering a spectral decomposition of
a similarity matrix. Finally, section 3.2.3 highlights one of the recently suggested
clustering methods, an affinity propagation, that is based on an iterative "message
passing" between the data points to be clustered.
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3.2.1 Agglomerative hierarchical clustering and Ward’s criteria
Agglomerative hierarchical clustering is a relatively simple class of traditional clus-
tering methods. Common for all the agglomerative clustering methods is the general
approach, where clusters are grown step by step by merging the previous clusters by
optimizing a certain criteria. At first, every data point belongs to its own cluster
and these clusters are merged step by step. Usually this iterative cluster merging is
continued all the way until only one cluster remains. By keeping track of the values
of the optimized criteria during the merges, it is possible to build a dendrogram, a
certain type of graph showing how the data points were merged into clusters (for
example see Figure 12 in section 5.4). Based on this dendrogram, it is possible to
gain insight to the structure of the data, and possibly the number of underlying
clusters. The final cluster assignments are made by "cutting the dendrogram" from
a certain level creating k clusters, which corresponds to stopping the cluster merging
after (n − k) merge steps. Therefore, the number of clusters does not have to be
predetermined, but it can be selected post hoc based on the dendrogram in order to
create meaningful cluster assignments.
There exist multiple different possibilities to select the cost function to be opti-
mized, and the selection heavily affects the resulting dendrogram and clusters. All of
the approaches have their own advantages and they are suited for certain problems.
However, it is hard to tell in advance which of the cost functions is most suitable for
the given data. Fortunately, there exists a measure, the agglomerative coefficient
(AC), that can be used to determine the quality of the resulting dendrogram as
introduced by Kaufman and Rousseeuw in [43]. To compute AC, first for each data
point i the ratio between cost function value at the first cluster merging and the cost
function value of cluster merging in the final step, denoted by m(i), is computed.
Finally the AC is defined as:
AC = 1
n
n∑
i=1
1−m(i), (7)
where n is the number of elements to be clustered, i.e. as the average of 1−m(i) over
all the initial clusters. The AC is limited to the interval [0, 1], where higher values
denote a good clustering. AC tends to have higher values when the number of data
points n increases, thus it cannot be used to compare clusterings of datasets of very
different sizes. However, there is no such bias when comparing different clusterings
of the same dataset. Later in this work, AC is used when selecting the most suitable
optimization criteria for the agglomerative clustering.
The traditional selection of the cluster merging criteria is based on single linkage
or complete linkage. In single linkage, the cluster distances are determined by the
pair of points that have the shortest between-cluster distance. On the contrary, in
complete linkage the between-cluster distance is the maximum distance between all
pairs of points between the clusters. Similarly, it is easy to set the between cluster
distance to the average or median of all the distances between clusters or as a distance
between cluster centroids. For example, the R package stats [44] offers multiple
of these cost functions implemented in function hclust. In this work, five of these
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criteria (single-linkage, complete-linkage, average-linkage, McQuitty’s, and Ward’s
criteria) were used. All of these approaches yield slightly different clusters, and they
prefer clusters of a different shape. Next, one of these, the Ward’s criteria, will be
introduced in more detail.
Among the agglomerative hierarchical clustering methods, Ward’s clustering is
the only one that is based on the classical sum-of-squares criterion [45]. Thus it
minimizes the within group dispersion at each cluster fusion. The cost function to
be minimized at each merge step is:
D(ci, cj) =
|ci||cj|
|ci|+ |cj| ||ci − cj||
2, (8)
where |ci| is the size of cluster i, and ||ci − cj||2 is the squared euclidean distance
between the cluster centers. Although the value of cost function is computed in
the euclidean space, an effective implementation based on the Lance-Williams dis-
similarity update formula allows the optimization of merges relying purely on the
dissimilarity matrix of the elements.
Two different implementations of the Ward’s criteria are found in literature, which
give slightly different results. In this work the algorithm implemented in R package
stats [44] in the function hclust as method=’ward’ in R v.3.0.2 is used with a
squared dissimilarity matrix, but the resulting dendrogram is rescaled using a square
root transformation in order to yield results corresponding to the original Ward’s
criteria, as discussed by Murthag et al. in [45]. Thus the results fully correspond to
using method=’ward.D2’ in R v.3.0.3 onwards. Scaling the height of the dendrogram
becomes important when computing the AC and comparing different clustering
methods.
3.2.2 Spectral clustering
Spectral clustering is yet another large family of clustering techniques. There exist
multiple different implementations and algorithms for them, however, the general
approach is mostly the same. First, the affinity matrix (or simply similarity matrix)
of the data is computed, and the graph Laplacian is constructed from this matrix.
Next, the eigenvalue problem is solved, and the k eigenvectors corresponding to the k
largest eigenvalues (where k is the number of desired clusters) are chosen. Finally, the
data is clustered in this subspace with a traditional clustering method, for example
by using the k-means algorithm [46].
In this work the method proposed by Ng et al. [47], implemented in R package
kernlab [48] as the function specc, is used and the technical details for this approach
are presented next.
The implementation allows either a precomputed similarity matrix (used directly
as affinity matrix K) or the raw data as an input. If the latter is used, the affinity
matrix K is first computed using a desired (user specified) kernel function. Next the
normalized Laplacian is computed as:
L =D−1/2KD−1/2, (9)
20
where D is a diagonal matrix of form Dii =
∑m
j=1Kij. Thus each diagonal element
is the sum of the corresponding row of the similarity matrix K. Then the first k
largest eigenvectors of the Laplacian L are computed, where k is the desired number
of clusters. These eigenvectors are used to create a n × k matrix Y , where each
column corresponds to one of the top eigenvectors in a decreasing order. The rows
of this matrix are further scaled to unity length. Finally each of these rows are used
as a coordinate representation of the original data points (row i corresponding to
the i-th data point in the original distance matrix) and clustered to k clusters by
using the k-means approach correspondingly. If the data contains clusters, they are
clearly separated in this spectral presentation, and the traditional clustering methods
applied in the last phase perform well in the task.
The clusters that spectral clustering can find are not restricted by shape or form,
and it can successfully cluster groups of an arbitrary shape and size opposed to using
only the traditional clustering methods. A good example of this is two intertwined
spirals (as presented by Karatzoglou et al. in [48]), circles within each other and
clearly connected shapes of an arbitrary form (as presented by Ng et al. in [47]).
Therefore, it is a good candidate for the clustering approach to be used when the
SOM prototypes are clustered, as no presumptions of the resulting clusters are to be
made.
3.2.3 Affinity propagation
The third and final clustering approach used in this work is the newest among the
different approaches examined. Affinity propagation was proposed in 2007 by Frey
and Dueck [49], and it has already been successfully used in many tasks in the field
of bioinformatics [50]. Affinity propagation is a prototype-based clustering method,
where the cluster centers are selected among the data points, and all the other points
are assigned to these "examplars" to form the clusters. The special properties which
the affinity propagation offers are that it simultaneously considers all the points as
potential examplars by "message passing" (thus avoiding randomness). It can also
find the examplars relying purely onto the similarity matrix without the exact vector
coordinates, opposed to most prototype-based clustering approaches. Furthermore,
the affinity propagation can determine the most suitable number of clusters during
the clustering, or it can be predefined by the user.
The algorithm by Frey and Dueck [49] has been implemented in R package
apcluster [50], with minor improvements on speed and flexibility compared with
the original implementation. Next the algorithm based on this implementation is
introduced.
First, the algorithm takes as an input the similarity matrix S of the elements to
be clustered. On the abstract level, each value Sik defines how well the data point
with index k is suited to be an examplar for data point i. This similarity matrix can
be arbitrarily defined real valued similarity (where also negative values are allowed),
and is not required to satisfy the properties of a metric or even to be symmetric. In
this similarity matrix, the diagonal elements Skk (referred in the original publication
[49] as "preferences") have a special role, as they affect how likely each of the points
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are selected as examplars. If each data point to be clustered is a priori as likely to
be an examplar, the diagonal values are to be set equal. However, the magnitude of
the values still affect the number of resulting clusters. Frey and Deuck suggest that
the input preferences are to be set to the median of the input similarities, or as the
minimum of them if a smaller number of resulting clusters is desired [49]. In the R
implementation the median is used as a default, but also a new optional argument q
is introduced. It defines the quantile of similarities to be used as an input preference
and thus allows a smooth transition between the two approaches originally suggested.
The clustering algorithm itself consists of iteratively updating two matrices, the
"responsibility" R and the "availability" A. Each element Rik of the responsibility
matrix presents the cumulated evidence for element k to serve as an examplar for an
element i. Correspondingly, each element of the availability matrix Aik presents how
suitable it would be for point i to select k for its exemplar, taking in account how
well the other points support k to be an exemplar at all.
First, the availabilities Aik are all initialized to zero. After this both matrices
are updated one after another, starting from the responsibility matrix as:
Rik = Sik −max
k′ 6=k
{Aik′ + Sik′}. (10)
Next, the availabilities are updated as:
Aik = min
0,Rkk +∑
i′ /∈{i,k}
max {0,Ri′k}
, (11)
with a special update rule for the diagonal elements:
Akk =
∑
i′ 6=k
max {0,Ri′k}. (12)
The message passing can be stopped after a predefined number of iterations,
after the magnitude of passed messages fall below certain threshold, or after the
local changes (examplars and examplar assignments) stay unchanged for a number
of iterations. For any step, point i can be identified to belong to cluster ck defined
by examplar k by:
ck = argmax
k
{Aik +Rik}, (13)
or being the examplar for the cluster ck if k = i. For further discussion, interpretation
of the message passing procedure, small alterations to avoid numerical oscillation, and
further comparisons with other clustering methods, refer to the original publication
by Frey and Deuck [49].
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3.3 Genetic data and analyses
The ultimate goal of this work is to compare the created novel phenotypes with each
other and find the exact genetic markers differing between the groups. Additionally,
the different clustering methods will be evaluated by their ability to distinguish
groups with different genetic background at a wider scale. Both of these tasks require
different methods to analyse the genetics of the novel phenotypes, which will be
further described in the following section. First, section 3.3.1 will introduce the
concept of array-based genome-wide genotyping, and the data that can be created
using this approach, which will be the base for the rest of the genetic approaches in
this work. Next, section 3.3.2 will introduce the statistical view of the heritability
measure, which will later be used to evaluate the performance of the clustering
methods. Thereafter, section 3.3.3 briefly will review the linkage structure of the
human genome and how it can be used to impute additional markers based on the
ones directly genotyped. Finally, section 3.3.4 will introduce the statistical tests used
to evaluate the genetic associations between case-control phenotypes.
3.3.1 Array-based genome-wide genotyping
The human DNA consists of approximately three billion nucleotides of genetic
code [51], that is mostly shared between individuals. However, many forms of
genetic variation exist. The most common and smallest form is a single-nucleotide
polymorphism (SNP), where one base pair of the DNA is changed to another. These
mutations are among the most studied, and are the target of GWASs.
For GWAS analyses, the genetic variant carried by each individual is to be
solved for hundreds of thousands to even millions of SNPs, in thousands of patient
samples. This can be achieved by using array-based genotyping approaches. One
of the providers of commercial genotyping arrays is Illumina, whose approach for
genotyping will be described in more detail next.
The base for the Illuminas approach is the BeadChip platform, where carefully
designed oligonucleotides (single strand DNA probes) are attached to small "beads"
(few µm in diameter) from their 5’ end. The different beads each contain probes of
only one type that will detect the DNA sequence next to the SNP to be genotyped.
These beads are then arrayed on a silicon surface on a regular grid, so that there
are multiple copies of each bead type across the array. Next the DNA sample to
be genotyped is preprocessed, fragmented, and added to the array as single strand
DNA. The DNA sequences in the bead probes will hybridize with these fragmented
sample strands only if the complementary DNA sequences match exactly. After
this, the fragments not hybridized are washed away from the array leaving only the
fused DNA fragments to the array, attached to the beads. Next, the bead probes
are extended by one nucleotide, which will match the SNP in the fused sequence.
The extended nucleotides are stained with fluorescent colors (A and T with one, C
and G with another), to differ between the variants. In addition, the chips contain
pairs of special probes with parallel detection method, that can also distinguish A/T
and G/C SNPs by design, where only one of the probes is extended in presence of
genotyped variant. After the extension, the array is imaged, and the signals from
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each bead are recorded. In case of a homozygous genotype, the signal will contain
only one of the wavelengths, and in case of a heterozygous genotype both of them.
Finally, these intensity signals are normalized and preprocessed, mapped to the
rs-codes of the SNPs, and the genotypes of the individual ("AA", "AB" or "BB")
will be called for each chip based on the data [52, 53].
The array technologies are constantly developing and improving in speed, through-
put and variety of SNPs captured. The array used to create the genotype data in
this work was the Illuminas Infinum CoreExome BeadChip, that can genotype more
than 550,000 SNPs, with an estimated throughput of 2,800 samples per week [54].
3.3.2 Heritability
From a technical point of a view, heritability is a population parameter describing
the proportion of the phenotypic variance attributable to the genetic variance. Even
though widely used in common speech to describe whether a trait can be passed
from a generation to another, in technical means it has a wider interpretation and
specific definitions as reviewed by Visscher et al. in [55].
The base for the following definitions is a model, according to which the phenotype
(P ) of an individual can be expressed as a sum of unobservable genetic components
(G) and unobservable environmental components (E) both affecting the phenotype
outcome: P = G + E. Thus, the variance in the observable phenotype σ2P can
be partitioned to variances by the genetic component σ2G and the environmental
component σ2E:
σ2P = σ2G + σ2E. (14)
The broad-sense heritability of the phenotype is defined as the ratio of the genetic
and phenotypic variance:
H2 = σ
2
G
σ2P
, (15)
thus, expressing the phenotypic variance attributable to the genetic variance. How-
ever, the genetic variance can be further divided into components describing the
additive genetic effect (σ2A), the dominant genetic effect (σ2D) and epistatic genetic
effects (σ2I , i.e. the interaction between alleles at different loci) as σ2G = σ2A+σ2D+σ2I .
Usually, instead of the broad-sense heritability, a narrow-sense heritability (also
referred as strict sense heritability, or just as heritability) is used, describing the
variance due to additive genetic factors:
h2 = σ
2
A
σ2P
. (16)
As the matter of fact, the partitioned phenotypic variance should also contain the
covariance of the genetic and environmental factors as well as the variance due to
G-E interaction. However, these are usually ignored as they cannot be estimated as
discussed in [55]. Later in this work, when the term heritability is used, narrow-sense
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heritability, i.e. the proportion of phenotypic variance attributable to additive genetic
factors, is referred.
Using genetic data from genome-wide genotyping, it is possible to estimate the
additive genetic variance by multiple different methods. One of the tools used
to achieve this is the Genome-wide Complex Trait Analysis (GCTA) software. It
uses the genetic relationship matrix (GRM) of unrelated individuals in a mixed
linear model to estimate the variance explained by the hundreds of thousands of
genotyped single-nucleotide polymorphisms (SNPs) via the restricted maximum
likelihood (REML) approach [56].
In the GRM, A, each element Ajk describes genetic relationship between individ-
uals j and k, defined as:
Ajk =
1
N
N∑
i=1
(xij − 2pi)(xik − 2pi)
2pi(1− pi) , (17)
where, xij is the number of copies of the reference allele of the i-th SNP for the j-th
individual, pi is the frequency of the reference allele, and the summation goes over
all the N genotyped SNPs.
The GRM defined this way is used in a mixed linear model of form:
y =Xβ + g + , with, (18)
var(y) = V = Aσ2g + Iσ2 , (19)
where y is an n × 1 vector of phenotypes of the n individuals, β is the vector of
fixed effects for the covariates X, and g is an n× 1 vector of total genetic affects of
the individuals with g ∼ N(0,Aσ2g). I is an n× n identity matrix,  is the vector
of residual effects with  ∼ N(0, Iσ2 ), and σ2g is the (additive) genetic variance
explained by all the SNPs, which is to be estimated via the iterative REML approach.
For the details of the implementation of the estimation method relying on an average
information algorithm, and further possibilities to partition the heritability to separate
chromosomes, refer to the original publication by Yang et al. [56].
Using this approach, GCTA can estimate the additive genetic variance and there-
fore the narrow-sense heritability captured by the genotyped SNPs (i.e. observable
with the used genotyping platform, thus, sometimes referred as array-heritability).
In this work, the GCTA (v.1.24.4) was used when computing heritabilities between
the novel phenotype classifications.
3.3.3 Genetic linkage and genotype imputation
Half of the genetic code in the DNA of an individual is inherited from the mother,
and the other half from the father. When the egg and sperm are created in meiosis,
parts of the DNA may change between the paternal and maternal chromosomes and
this mixture of DNA will be later inherited to the next generation. This crossover of
DNA can happen almost all around the genome, but the DNA sequences between
two of these crossovers are inherited as a whole. However, the occurrence of these
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crossovers are not totally random. The human DNA contains multiple so called
recombination hotspots, where these crossovers happen more frequently than in
the surrounding regions. Thus, the long DNA sequences between these hotspots
are usually inherited directly from a generation to the next in a single haplotype.
Thus genetic variants in same haplotype and close-by regions tend to correlate with
each other. This phenomenon is called linkage disequilibrium (LD), and it is taken
advantage of in genotype imputation.
The SNPs selected in the array-based genotyping methods are based on the
relatively well known haplotype structure of the human genome, so that each of
the genotyped SNPs will also capture the structure of the nearby genetic region.
However, this property can also be used to predict genetic markers not being directly
genotyped in the samples. The basic idea is to observe the successfully genotyped
SNPs of an individual, and compare them to reference genomes with a tighter SNP
panel genotyped (for example from the HapMap [57] or 1000Genomes [58] studies) to
solve the haplotype of the individual. In many of the cases, it is possible to find with
high confidence the corresponding haplotype, and thus predict the most likely variant
of nearby SNPs with high confidence, i.e. impute the missing variants. Imputing
the genotype data can help both the fine mapping of regions around the genotyped
SNPs (i.e. increase resolution), and by increasing the overall power to detect the
genetic associations [59, 60].
In most of the approaches, the methods yield three different probabilities (summed
to one) for every variant: the probability of a patient to be homozygous (paa for
being homozygous for the minor variant and pAA for being homozygous for the major
variant) and the probability of the patient to be heterozygous (pAa). These genotype
probabilities can be used directly in certain analysis methods, or sometimes the most
likely genotype is selected to be used as such. Another widely used approach is to
transform the genotype probabilities to genetic dosages as:
D = 0× pAA + 1× pAa + 2× paa. (20)
This dosage is a continuous extension of the count of minor alleles, and it is restricted
to the interval [0, 2], but captures also the possible uncertainty of the imputation
(compared with using most likely genotypes directly). It can be used in many analysis
settings similarly as the counts of directly genotyped SNPs, as next presented in
section 3.3.4.
3.3.4 Genome-wide association analyses for case-control setting
The goal of Genome-wide association study (GWAS) analyses is to test multiple (up
to tens of millions) genetic markers for their association with the phenotype of interest
in a large population of unrelated individuals. There exist multiple different tests and
models to evaluate genetic association in different settings. However, in the GWAS
setting the analysis is usually performed by testing every genetic marker independently,
in order to make the analyses scalable. The number of possible genotype combinations
increase rapidly if more genetic markers are considered simultaneously, and therefore
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the required time for computation would become quickly infeasible in a genome-wide
setting using other approaches.
Even when the approaches are limited to single marker tests, the selection of
available tools is wide. In this work we consider only one of the most widely used
tools, PLINK [61, 62], and the test models it implements. We further restrict the
theory to testing binary traits, as all the phenotypes created in this work are treated
as such.
The simplest form of association testing implemented in PLINK performs a
chi-squared test with one degree of freedom to the allele frequencies between cases
and controls for every genetic marker separately (initiated with --assoc flag).
PLINK has also models implementing Fischer’s exact test, Cochran-Armitage
trend test (dividing the table to three based on genotype) and different models of
inheritance (dominant or recessive, further grouping the genotype columns of count
tables). However, all of these approaches suffer from the limitation that they cannot
include any covariates to the model. Thus it would be impossible to include the effect
of the known risk factors, or different confounding factors, and correct these analyses
for their effects. Thus, if an additive genetic model is desired, a logistic regression is
used instead of the models mentioned previously due to its flexibility and ability to
include covariates into the model. In this approach, a logistic regression line,
F (x) = 11− e−(β0+β1x) , (21)
is fitted to the data, where β0 is the intercept, β1 is the regression coefficient for
the genetic effect and x is the genotype (count of minor alleles). Now F (x) can be
interpreted as a probability of an individual being a case given the genotype x, as
the logistic function maps all the real values to the interval [0, 1]. If the equation is
solved as follows:
F (x)
1− F (x) = e
β0+β1x, (22)
the left hand side of the equation is the odds (proportion of probabilities) of the
patient being a case (versus not being a case). Using this idea it is possible to define
the odds ratio (OR) for a genotype containing one additional copy of the effect allele
(compared with a genotype with one copy less):
OR =
F (x+1)
1−F (x+1)
F (x)
1−F (x)
= e
β0+β1(x+1)
eβ0+β1x
= eβ1 . (23)
Thus, the resulting exponentiated fit coefficient β1 is to be interpreted as an odds
ratio for the disease risk, i.e. a multiplier for risk for each copy of the genetic variant.
The statistical significance for genetic association is the two sided p-value from a
hypothesis β1 = 0.
Using this model it is possible to add the effect of other factors by:
F (x1, x2, ..., xn) =
1
1− e−(β0+β1x1+β2x2+...+βnxn) =
1
1− e−βx = F (x), (24)
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where x2, ..., xn are the additional covariates included in the model, and β2, ..., βn
are the corresponding regression coefficients. Corresponding to the model without
additional covariates, β1 and x1 are the genotypes and regression coefficient for the
genetic effect. The interpretation of the results and the statistical significance for
genetic association are also the same. This model is implemented in PLINK and can
be initiated with the --logistic flag. This approach can be applied directly also to
continuous genetic dosages resulting from genotype imputation, and such an analysis
can be initiated with --dosage flag in PLINK.
As this widely used GWAS analysis approach is based on single marker testing,
the results should take into account the problem of multiple testing. However, this is
not straightforward in genetic association testing, as nearby markers correlate with
each other due to genetic linkage (for more details see section 3.3.3), and thus the tests
performed for two SNPs in LD are not completely independent. Thus, the GWAS
analyses have widely accepted p-value of p < 5× 10−8 as a significance threshold for
association, corresponding to a Bonferroni correction of an approximated one million
independent SNPs in the European population (p < 0.05/1, 000, 000 = 5× 10−8) [63].
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4 Materials and methods
The base for this work is the comprehensive data collected from patients with T1D
during the FinnDiane study. In this work, different computational methods are
applied to this large dataset in order to create novel patient classifications. These
new classes are further used in genetic analyses, with the goal to find genetic variants
that could help to explain the pathophysiology and causes behind the diabetic
complications. The following section describes in more detail the data and how the
different methods were applied.
First, section 4.1 describes the FinnDiane Study, and the collected datasets that
were used in the analyses of this work. Next, section 4.2 describes how the data was
preprocessed, how the multi-layer SOM was trained, and how its parameters were
selected. Then, section 4.3 describes how the prototypes of the trained SOM were
clustered, how the different clustering methods were evaluated, and how the most
suitable method was selected to be used to create the novel phenotypes. After this,
section 4.4 goes through how the novel phenotypes of diabetic complication profiles
were created, and finally section 4.5 describes the GWAS analyses performed for
them.
4.1 The FinnDiane Study
This work is a part of the FinnDiane Study (1997–), which is an ongoing nationwide
multicenter study of T1D and its long-term complications with the aim to define the
clinical, environmental and genetic risk factors of diabetic complications with special
emphasis on DN. The number of volunteer patients with T1D in the study is currently
more than 7,000 and continuously increasing, which represents approximately 15-20%
of the population with T1D in Finland (approximated to be currently roughly 40,000
patients). The comprehensive study protocol and patient recruitment have been
described in more detail before [64]. Briefly, adult patients with T1D have been
recruited by their attending physicians through 77 hospitals and primary healthcare
centers (all five university hospitals, all 16 central hospitals, 26 other hospitals and 30
primary healthcare units) across Finland. During the recruitment process, multiple
questionnaires are completed by the physician and the patients themselves, and both
blood and urine samples are collected. Currently, more than 5,000 patients have been
recruited this way. In addition, the FinnDiane study includes close to 2,000 patients
recruited through the Finnish National Institute of Health and Welfare (THL) across
Finland. The overall distribution of the recruited patients in the study follows closely
the general population distribution of Finland as shown in Figure 4.
On top of the still ongoing patient recruitment, the prospective phase of the study
started in 2004 calling the patients back for a follow-up (FU) visit. Thus far, more
than 1,800 patients have also FU data collected. For this follow-up, samples and
questionnaires corresponding to the baseline visit are collected. Additionally, the
FinnDiane study uses the medical records and multiple national registries, linked
via the personal identity code of the patients, to continuously update the clinical
phenotypes of the participants.
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Figure 4: The distribution of the patients in the FinnDiane Study (left) and the
distribution of the general population in Finland (right). Figures from [65] and [66],
correspondingly.
Furthermore, a large proportion of the FinnDiane patients, including the patients
recruited through THL, have an array based genome-wide genotyping performed on
them. This data is further described in section 4.1.2.
The study protocol of the FinnDiane Study has been approved by the local ethnics
committee, all the studies are conducted in accordance of the Declaration of Helsinki,
and all the patients gave their informed consent prior to enrolment.
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4.1.1 Clinical variables and patient inclusion
For this study, only the patients recruited through the FinnDiane recruitment process
described above were selected, and the patients recruited through THL were excluded
due to limited data on variables required for the analyses of this study. The patients
were further excluded unless they fulfilled the generally used criteria for T1D:
• Age at diabetes onset < 40 years
• Insulin treatment initiated within one year of the diagnosis
This way, the patients with plausible T2D were excluded from the further analyses.
Additionally, patients without genotype data were excluded in the initial screening.
For the remaining patients, the clinical data collected throughout the FinnDiane
Study was extracted from the FinnDiane database. As the data is constantly collected
and new patients are recruited, the data was frozen at the 21st of October, 2015, and
this data was used throughout the rest of the analyses. The data included measures
from both the baseline (BL) visit and the follow-up (FU) visit as well as the latest
available clinical phenotypes derived from registries and other clinical sources.
Within the extracted data, the form filled out by the attending physician included
variables measured at routine clinical examinations (for example anthropometric
measures and blood pressure levels), variables describing different clinical compli-
cation phenotypes at the time of the visit, variables describing medication and
insulin treatment of the patient, and some family and pedigree related questions.
Correspondingly, the self-report questionnaire contained some complication related
questions, a wide range of questions related to diet and life style (such as smoking,
alcohol usage, education and employment), and a wide panel of questions related to
family history of diabetes and its complications.
The datasets of the laboratory measures of the blood contains variables describ-
ing lipid profiles of the blood, serum concentrations of different general markers,
a few inflammatory markers, as well as some diabetes specific markers (such as
glycated haemoglobin, HbA1c, describing the long-term glucose management of the
patient). Correspondingly, the laboratory measures from the urine samples consisted
of variables describing electrolyte and protein concentrations of the urine samples,
collection specific variables (time and volume), as well as some diabetes and DN
specific markers (such as urine KIM-1 concentrations).
Finally, the registry based data contained variables derived from Statistics Finland
(latest vital status of the patient until 31st of December 2014), and the Hospital
Discharge Register (HILMO, phenotypes for cardio- and cerebrovascular events until
31st of December 2013). Additionally, the data included the latest clinical phenotype
definitions for DN collected and combined from multiple sources by other members
of the FinnDiane group (sources such as Finnish Kidney Disease Registry, HILMO,
other clinical patient data, dates for latest data varying).
All this data was combined and pruned as described later in section 4.2.1.
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4.1.2 Genome-wide genotyping and genotype imputation
A total of 6,255 patient samples in the FinnDiane cohort have genome-wide geno-
typing performed for them at the University of Virginia, using Illuminas Infinum R©
CoreExome BeadChip. The used chip contains all the highly informative tagSNPs
from Illuminas HumanCore BeadChip, as well as a wide panel of exome markers
from Illuminas HumanExome BeadChip. Overall, the used chip contains probes for
approximately 550,000 SNPs [54].
The genotyping of the FinnDiane samples was performed in three different
batches. Genotype calling and comprehensive quality control (QC) was performed
for each batch separately at the university of Virginia by a third party member.
This QC filtered both poor patient samples (testing multiple quality criteria such as
low genotyping rate, possible sample mix-ups, extreme heterogeneity, and gender
error) and SNPs with poor quality (such as low genotyping rate, markers not in
Hardy–Weinberg equilibrium, and markers associated with gender issues). These
three batches were merged in FinnDiane, including only SNPs and patients that
passed QC in each batch separately. In this merging the SNPs were further filtered
based on batch association and finally all monomorphic SNPs were removed from
the data. This merged data contains a total of 6,010 patients passing the QC and
more than 300,000 SNPs with a higher than 99.95% average call rate. This data
from direct genotyping was used to later compute the heritabilities of the defined
novel phenotype classes.
This data was also imputed by a third party member using Minimac3 software
(version 1.0.13) with 1000 Genomes Phase 3 version 5 genotypes (updated on 20th of
October 2015) as a reference genotype panel. The imputed data contains approxi-
mately 8.7 million SNPs with sufficient imputation quality (PLINK INFO information
criteria > 0.8) for the patients, of which approximately one million are rare (minor
allele frequency MAF < 1%), 1.7 million relatively uncommon (1% < MAF < 5%)
while the rest (6 million) are common. The imputed data was used in the GWASs to
pinpointed the genetic markers associated with class assignments.
4.2 SOM of patients with T1D
The comprehensive clinical data collected in the FinnDiane study was used to train
the dual-layer SOMs that created the core for this work. Data from two different
time points was used in the two different layers of the SOM, in order to capture
also the progressive nature of the diabetic complications. The resulting prototype
profiles of the trained SOM were clustered into varying number of classes. The
trained prototypes were also used to map the individual patients back to the SOM,
and to solve in which of the created classes each individual belongs. The following
subsections will present the preprocessing of the clinical data, how the free parameters
of the SOM were selected, and how the SOM was trained.
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4.2.1 Variable pruning and data normalization
First, all the data was combined from different sources: questionnaires filled out
by the attending physicians, self-report questionnaires, laboratory measures from
blood and urine samples, and data from national registries. After this, the variables
describing latest clinical complication status were separated as outcome variables
and pruned later by their missingness in the remaining patients. Meanwhile, the rest
of the variables (the input variables) were further filtered by including only numerical
and class variables (either binary, categorical, discrete or continuous) before further
pruning.
In the next step, both the remaining input variables (data matrix columns, m)
and the patient visits (data matrix rows, n) were pruned based on the missingness
without further consideration of the possible clinical relevance of the variables in
order to avoid possible selection biases. The patient visits, BL and FU, and the
corresponding measured variables were pruned in separate batches simultaneously.
An iterative approach was applied, where the pruning threshold was slowly increased
in ten steps starting from 1%, until a patient-wise non-missing fraction of 1/2 and a
variable-wise non-missing fraction of 1/3 were reached. For each step, if a variable
would have been pruned only in either the BL or FU dataset, it was removed from
both datasets instead, in order to keep the included variables the same at the different
time points. The iterative increase in pruning threshold was applied as the raw data
contained both patient visits and variables with almost completely missing data, that
would cause overestimated missingness and thus prune variables and patient visits
close to the desired cut-off levels if direct cut-off threshold was used. At this point,
the categorical variables were transformed into sets of binary variables.
Next, all the variables were tested for their linear independence using a sub-
sample of the patient visits with complete data for all the remaining input variables
passing the missingness threshold. The testing was performed by fitting a linear
regression model, where each of the variables were used as a dependent variable
one at a time and all the other variables were used as explanatory variables. If
the model explained the dependent variable using the other variables with a large
coefficient of determination (R2 > 0.95), it was considered to be linearly dependent.
After the linearly dependent variables were identified, they were manually pruned
until no such dependencies were observed for any of the variables. In this selection,
biologically redundant sets of variables were pruned, preferring original measures
over derived values. For example the systolic blood pressure (SBP) and the diastolic
blood pressure (DBP) were preferred over the mean arterial pressure (MAP), which
all have a linear dependency of the form MAP = 13(SBP + 2 × DBP). Excluding
the directly derived variables eliminated most of the linear dependencies, and for
the rest, within the sets of variables creating the dependencies, the ones with more
missing values in the full dataset were pruned off. Furthermore, all variables that
were known as non-linear transformations of the included variables were further
filtered (for example 24h urine excretion rate for any substance is computed by:
concentration × 24h urine collection volume / collection time). In addition, some of
the urinary markers were transformed to ratios compared with urinary creatinine
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as these ratios are clinically more relevant than the pure concentrations of these
markers which are heavily affected by the urine volume.
Finally, all the outcome variables describing the latest clinical phenotypes were
pruned by the missingness, requiring more than 50% non-missing values for the
patients passing the input variable pruning.
This way, three sets of variables were created:
• Baseline data of variables corresponding to the measures of the BL visit when
the patient entered the study (the input variables for 1st SOM layer)
• Follow-up data of the patients several years after the BL visit (median 6.3
years, IQR 5.0-7.6 years) with variables corresponding to the BL visit (the
input variables for 2nd SOM layer)
• Latest available data of clinically defined diabetic complication diagnoses and
mortality of the patients (the outcome variables)
The first two datasets were used as an input data in the training of the SOM and
mapping of the patients, whereas the third dataset was used to evaluate the perfor-
mance of the patient classification for the prognosis of mortality and complication
status.
Before introducing the data to SOM, it is important to perform a meaningful
scaling and preprocessing for the whole data. It has been shown that when SOM
approaches are applied to clinical measures, such as in this work, the clear differences
between genders in certain variables can direct the training of the SOM, suppressing
clinically more relevant phenomena [67]. For example a woman’s body contains
on average more fat compared with a man’s, which affects the distribution of lipid
profiles, and men are on average taller than women. Thus, these gender differences
were first masked as described in [67] by rank transforming and scaling the continuous
variables. To achieve this the BL and FU datasets were handled separately. First,
the dataset at hand was divided into males and females. Then, for each continuous
variable, the values were ranked (in gender specific subsets), and the ranks were scaled
to the interval [−1, 1]. Next, these scaled ranks were transformed as x = (z3 + z)/2
after which the male/female subsets were merged again. The transformation of
scaled ranks mimics the Gaussian probability density making it compatible with the
Euclidean distance metric used in the computation of the distances to BMU in the
SOM algorithm [66]. On top of masking the gender related differences, this approach
also normalizes the shape of skewed distributions as well as handles extreme outliers
so that they do not disturb the SOM training. Additionally, all the variables (binary,
discrete, and already rank transformed continuous) were standardized to have a zero
mean and an unit variance in the combined dataset of both genders.
Of this data, all the patients containing both BL and FU visits were used as
training data for the SOM, and all the rest (containing either BL or FU data only)
were used as test data when the SOM performance was evaluated.
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4.2.2 Selection of SOM parameters
In this work, a toroidal-hexagonal grid was selected as the SOM topology, as the
toroidal topology should create a smoother distribution of the resulting prototypes as
there are no edges and corners for extreme profiles to escape. Indeed, empirical pilot
analyses show that using a non-toroidal grid seems to create scattered (disconnected)
clustering of the trained SOM-prototypes more easily, which is undesirable in the
scope of the goals of this work (data not shown).
The size of the selected SOM was determined based on the "rule of thumb"
presented in section 3.1.1. When the pair of rules,
m = 5
√
n = wh, (25)
w
h
= λ1
λ2
, (26)
are solved for h and w, the height and width of the map are set according to:
h =
√
5
√
nλ2
λ1
, (27)
w = 5
√
n
h
, (28)
where λ1 and λ2 are the two largest eigenvalues of the covariance matrix of the input
data, and n is the number of training vectors. When computing this covariance
matrix, only the pairwise complete observations for pairs of the variables were used
due to the missing data. However, in order for the toroidal hexagonal grid to fold
correctly, an even height for the grid is required. Thus the rule for height h and
width w were slightly altered and set according to:
h = 2
1
2
√
5
√
nλ2
λ1
 , (29)
w =
⌊
5
√
n
h
⌋
. (30)
As a dual-layer SOM was used, the height and width were computed based on
eigenvalues from both the BL and FU datasets corresponding to the different layers
(and thus different data matrices), and the resulting height and width values closest
to the desired number of nodes m = 5
√
n were selected.
The prototype positions were also initialized randomly in order to test the
robustness of the approach. The random initialization implemented as a default in
the used kohonen package was selected. In this approach, the starting points of the
grid nodes are drawn randomly without replacement from the training data [42].
For the neighbourhood function, the radial function presented in Equation (4) was
selected, implemented as default in the kohonen package. For the learning rate, the
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default value of the kohonen package was used. Therefore, it will decrease linearly
from 0.05 to 0.01 through the training iterations. The number of training iterations
was optimized, during which the decrease of the neighbourhood function was kept in
default values, i.e. the size of the neighbourhood started as containing two thirds of
the map units and decayed linearly so that after approximately half of the iterations
only the winning unit was adjusted. However, after the most suitable values for
the training iterations were selected, the proportion of fine tuning (i.e. the rate of
decrease in the neighbourhood function) was altered as described later.
To avoid under and/or over fitting, the number of training iterations was altered
from the default values of the kohonen package. The default implementation intro-
duces every training vector 100 times to the SOM to be trained, but this can be
altered by the rlen parameter. First, a reasonable range of times that the training
vectors would be presented to SOM was selected rlen = {50, 100, ..., 750}. Then
for each of these, n = 100 SOM maps were trained (using the default values for the
neighbourhood radius decrease), using patient data with both BL and FU measures
as training data and the rest as testing data. Both the QE and the TE of the testing
data and the used training data was stored for each of the iterations. The lower
bound of the range was selected as 50, because this resulted in a slightly smaller
than recommended number of training steps, at least 500 times the number of nodes
in the SOM, as suggested by Kohonen (see section 3.1.1). The number of maps to
be trained, step size for rlen and upper bound were selected as such, as the time
required for the computation has a complexity of O(n×∑ rlen). Thus, shortening
the step size or adding large values to rlen would have a major effect on the com-
putation time, with only minor improvements to interpretation. Using these values
took approximately 4 days to compute using an average computer with Intel Core2
Quad CPU Q9500 processor running at 2.38GHz, 4.00 GB of RAM and the Windows
7 operating system. The most suitable number of training iterations was selected
based on the QE and TE values. As the kohonen package has not implemented TE
for the multi-layer SOM, it was computed using custom scripts (both fraction and
distance based measures). This approach to select the number of training iterations
was motivated by the assumption that increasing the number of training iterations
should decrease the errors in the training data, and for the testing data the values
should first decrease, until an increase (or no further decrease) is observed, indicating
that further training is not required.
As the TE was observed to increase if the number of steps during fine tuning phase
(when only the winning node is moved) was increased (see section 5.1 for details),
also the decrease in the neighbourhood function radius was optimized as follows.
After the optimal number of training iterations was selected, different proportions
of steps used for the fine tuning phase were selected (95%, ... 10%, 5% and 0% of
the overall iterations steps) and another 100 SOM maps corresponding to each of
these were trained using the same training and test data. Similarly as optimizing the
number of training steps, the TE and QE of the resulting mappings were recorded
and averaged over the runs. The final proportion of steps used in the fine tuning
phase was selected based on these values.
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4.3 Prototype clustering
In this work, the prototypes of the trained SOM mapping were clustered using three
different methods: agglomerative hierarchical clustering, spectral clustering, and
clustering by affinity propagation.
For agglomerative hierarchical clustering, first all the different methods creating
dendrograms without possible reversals offered by the R package stats [44] as a
function hclust were tested for their performance. These included five different cost
functions: single-linkage, complete-linkage, average-linkage, McQuitty’s, and Ward’s
criteria. In order to find the most suitable criteria among these, 100 SOM maps were
trained using the training data, and the resulting prototypes were clustered using
each of the aforementioned criteria. The resulting values of AC were stored for every
iteration, and the merging criteria with the largest AC on average was selected to
be used in agglomerative hierarchical clustering. The AC was computed using the
function coefHier from the R package clusters [68], and since R version 3.0.2 was
used, the height of the dendrogram by Ward’s clustering was square root transformed
before the AC was computed. The input distance matrix for every clustering method
was defined as the distance between prototype nodes averaged throughout the
different SOM layers (except for Ward’s criteria, where the implementation requires
this distance matrix to be squared in R version 3.0.2 or earlier). For additional
information on the special treatment of the Ward’s clustering, see section 3.2.1.
For the second method, spectral clustering, the implementation in the R package
kernlab [48] as a function specc was used. The similarity matrix was defined by first
computing the average distance throughout the layers as in agglomerative hierarchical
clustering, and then negating the distance matrix creating a similarity matrix. As
the used implementation of spectral clustering requires an input with non-negative
values, the matrix was further scaled by subtracting the minimum (negative) value
of the matrix from all the elements, thus creating a matrix with non-negative values
only. This similarity matrix was used directly as an input for the method and the
number of clusters were defined using the clusters parameter. Otherwise default
parameters were used.
Finally, for the affinity propagation, the implementation in R package apcluster
[49, 50] and function apclusterK were used, in order to allow the number of desired
clusters to be predefined. The negated average distance matrix throughout the layers
was used as an input, as affinity propagation can also handle matrices with negative
values. The number of clusters were defined by the parameter K, and otherwise the
default parameters of the implementation were used.
4.3.1 Evaluation of the clustering performance
The performance of the different methods used to cluster the prototypes of the
trained SOM were evaluated by both their robustness to classify patients into the
same clusters, and by their ability to distinguish patient classes that show genetic
differences between the resulting classes.
As the resulting SOM prototypes depend on the random order of the presented
training vectors, the resulting mapping is random by definition. However, if the
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parameters of the SOM are correctly selected and the data cloud indeed shows
some structure, the resulting SOM mapping should be similar throughout different
iterations of the algorithm and capture the global structure relatively well. Still, the
small differences in the resulting prototypes can have notable effects on the resulting
clusters and therefore on the groups where the mapped patients finally end up. This
is not desirable and thus the clustering methods were evaluated by their robustness.
In this work also the initialization of the SOM was random, and thus the differences
in the robustness of the clustering methods can be detected more easily compared
with a fixed (for example PCA projection based) initialization of the SOM.
In order to test robustness, 1,000 SOM maps were trained using the available
training data. For each iteration, the prototypes of the trained SOM were clustered
into two classes using the three clustering methods presented in section 3.2. After
this, all the patients (both the training and test data) were mapped to the trained
SOM, and the resulting class assignments of each patient were tracked throughout the
iterations. As the clustering methods are unsupervised and the resulting clusters do
not have labels, for each iteration the labels of the resulting group assignments were
inverted if this resulted into a larger proportion of matching assignments compared
with the classes of the first iteration. This way, it was possible to determine for every
patient how often that patient was classified into the same group during the iterations.
The robustness of the methods were visualized by plotting the cumulative curves of
the proportion of patients (including training and test data) robustly classified as a
function of the proportion of assignments to the same class. Robustness testing was
done using only two clusters as altering and keeping track the corresponding cluster
assignments in case of more than two clusters is not straightforward.
As one of the main goals of this work is to find the genetic differences of the created
novel phenotypes, it is important that the selected clustering method can indeed
distinguish patients with a possibly different genetic background. This was evaluated
by computing the heritability estimates of the resulting two-class assignments using
the GCTA software. For this analysis, the genetic relationship matrix (GRM) was
computed for the given set of patients using autosomal genotyped SNPs with a MAF
greater than 1%, after which it was pruned to contain unrelated individuals only
(using flag --grm-cutoff 0.025). This pruned GRM was then used in the restricted
maximum likelihood (REML) analysis to estimate the narrow-sense heritability of
the class assignment. These evaluations of the heritability were performed for the
two-class phenotype assignments defined by two different approaches described below.
In the first approach, the patients ending up in the same cluster more than 80%,
90%, 95%, and 99% of the time during the robustness iterations described above
were used as cases and controls. The heritability of the case-control groups defined
this way was computed for each of the three clustering methods. This approach was
motivated by the assumption that the most extreme patients would have the largest
genetic differences and further be most robustly distinguished by the SOM. Thus
excluding the intermediate patients that could not be robustly classified by the two
classes should make the possible genetic differences more clear, therefore helping to
detect the clustering method which creates patient classes with the largest genetic
differences.
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To complement the first approach, also the best fit of the SOM was selected
throughout the iterations. This was done by computing the QE and TE of each
mapping during the iterations and selecting all the SOM mappings having both QE
and TE below the average over the iterations (thus removing bad mapping outliers)
for the second phase. In the second phase, the QE and TE values for the remaining
SOM mappings were scaled to the interval [0, 1] and the mapping with smallest
distance from origin in this distance plane was selected as the optimal mapping.
Next, the prototypes of this optimal mapping were clustered into two classes using
all three clustering methods. Finally, these case-control phenotypes of the best fit of
the SOM (thus now including all the patients) were evaluated for their heritability
using GCTA with corresponding parameters.
Finally the most suitable method to create the final novel phenotype definitions
was selected according to its robustness, the ability to distinguish genetically differing
patient groups, and overall performance.
4.4 Defining the novel phenotypes and their differences
After the most suitable clustering method and the optimal SOM mapping were
selected during the iterations described above, they were used to create the novel
phenotype classifications. The prototypes of the optimal SOM mapping were clustered
by the selected method by specifying a different number of clusters (k = {2, 3, 4, ...}).
For each k, all the patients included in the study (both training and test data) were
mapped back to the trained SOM map, and the phenotype of each patient was
assigned according to the BMU cluster assignment. After this, the heritabilities
between each pair of defined patient groups were evaluated, once again using the
GCTA software and the approach and parameters described above, in order to detect
clusters that show genetically divergent patient populations. The number of clusters
was increased until there was no further motive to increase k. All the pairs of
clusters showing significant heritability (using a Bonferroni corrected significance
threshold corresponding to the number of tests for the current cluster number, i.e.
p < 0.05/[12k(k−1)]) were further analysed as a case-control phenotype in the GWAS
setting described in section 4.5.
The performance of the resulting clustering was also evaluated by visual inspection
of the SOM-layers and statistical testing of input and response variable distribution
differences in the created classes.
The visual inspection of variable components was achieved by mapping all the
patients to their BMUs and computing for each node the mean (or prevalence for
binary traits) of each untransformed input and outcome feature in both the BL and
FU layers. After this, both layers were coloured according to the trait magnitude from
a 1% winsorized distribution across all nodes (computed using function Winsorize
from R package DescTools [69]) in sense of a heat map. Inspecting the heat maps
helped to detect for example variables whose distribution changes between BL and
FU layers, variables that seemed to follow the created cluster borders, variables
whose distribution seemed parallel to created cluster borders, and variables that did
not seem to have a significant structure in the component planes at all.
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These differences were also tested by fitting generalized linear models (using R
function glm from the package stats [44]) for each variable (Vj) separately, where
both the created phenotype class (Ci, set of dummy variables corresponding to the
categorical variable) and the SOM layer indicator (L, binary variable indicating FU
layer) were included in the model with their interaction terms for each input variable,
i.e.
Vj ∼ β0 +
k∑
i=2
β1iCi + β2L+
k∑
i=2
β3iCiL, (31)
where βij are the corresponding fit coefficients of each component. Thus the group
1, BL layer, and the interaction in change from BL to FU layer in group 1 were
the references. For binary variables, the modelling was done using the logit link
function and for other variables using the gaussian identity link function. The data
for continuous variables were 1% winsorized to constrain the effect of outliers. After
the modelling, the coefficients for the groups were tested for hypothesis,
β12 = β13 = ... = β1k = 0, (32)
using Wald’s test (from R package aod [70] using fuction wald.test) to evaluate
whether there are group(s) that differ(s) among the created classes, similarly to
ANOVA (but now applicable also for binary variables). Correspondingly, the in-
teraction terms were combined and their effect was tested using Wald’s test for
hypothesis
β32 = β33 = ... = β3k = 0, (33)
to test whether the change in variable distribution from the BL to the FU layer
behaves differently for any group compared with the rest. For k = 2 the only resulting
coefficients for group and interaction were interpreted directly for their significance.
The significance threshold was Bonferroni corrected for the total number of variables
modelled, i.e. set to p = 0.05/(m|k|), where m is the number of input features in the
SOM, and |k| is the number of different clusterings created.
4.5 Genetic analyses
Finally after the pairs of clusters showing a significant heritability were identified, the
unrelated patients used in the heritability computations were used in a case-control
GWAS analysis with the defined cluster assignment as a binary phenotype. For these
analyses, PLINK v.1.07 was used with the imputed genotype data (described in more
details in section 4.1.2) with logistic regression models (described in more details in
section 3.3.4) for continuous genotype dosages. The models were adjusted for sex,
the genotyping batch of the patient, and the first ten genetic principal components
(PCs) of the genetic data, computed using the Eigenstrat software (EIGENSOFT
v.3.0) [71]. Only SNPs with MAF above 1%, and imputation quality (PLINK INFO
criteria) above 0.8 were analysed.
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5 Results
The following section will present the results of the analyses in this work. First,
section 5.1 presents the variables used to train the multi-layer SOM, and how the
SOM parameters were selected. Next, section 5.2 visualizes the distribution of
multiple input and output variables in the optimal SOM mapping, and evaluates the
ability of the multi-layer SOM to capture the progressive nature of the complications.
Section 5.3 presents the results of performance for different clustering methods, both
in their robustness and ability to distinguish groups with a genetically divergent
background, and how the most suitable method was selected. Then, section 5.4
illustrates the resulting cluster assignments in the optimal SOM mapping and the
evaluated intergroup heritabilities between the defined classes. After this, section
5.5 illustrates the profile differences of the patients mapped to the created classes.
Finally, section 5.6 summarize the results of GWAS analyses between the novel
phenotype classes.
5.1 Training variables and optimized SOM parameters
After all the raw data from different sources were combined, the iterative process to
prune the variables and patient visits with too much missing data was performed.
After this, a total of 97 input variables remained for a total of 6,013 patient visits
(BL: 4,372, FU: 1,630) for a total of 4,409 unique patients. Of these 1,600 patients
had both BL and FU data present, 2,779 patients had only the BL data and a further
30 only the FU data (BL visit excluded due to missingness constraints).
After this, the subset of patient visits having complete data for all of the variables
(n = 728) was used to prune the linearly dependent variables, and the variables
derived using other variables included in the set. After this pruning, a total of 18
variables were removed from the data, and thus n = 79 variables remained, and were
later used as input variables for the SOM. In the combined set of BL and FU data,
the variable with the most missing data contained 51% non-missing values, and the
overall proportion of non-missing entries in the data matrix was 92%. All of the
selected variables and their missingness values are presented in Appendix A.
After the data was pruned successfully, it was further transformed and standardized
as described in section 4.2.1. Next, the size of the used SOM grid was defined from
the standardized input data matrices as described in section 4.2.2, and set as 10× 18
nodes (height × width). After this the number of training iterations was optimized as
described before. The QE and TE across the optimization iterations are illustrated
in Figures 5a and 5b.
As Figure 5 illustrates, increasing the number of training iterations decreases
the QE of both training and test data. Furthermore, when setting rlen = 700
the SOM seems to yield the smallest QE on average, and this error increases to
significantly worse when rlen is increased to 750 (p = 0.021, Welch Two Sample t-
test). However, it seems that increasing the number of training iterations will increase
the TE of the SOM (both in training and testing data) from the very beginning.
The phenomenon of increasing TE is very likely due to the fact that the default
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Figure 5: Average QE (a) and distance based TE (b) as a function of the number of
training iterations during the the rlen parameter optimization. * p = 0.021
decrease in the neighbourhood function in the kohonen package is implemented
so that the number of fine tuning iteration steps (when only one of the nodes is
moved) is always approximately half of the training iterations, and thus the absolute
number of such iterations increase when the number of training steps is increased.
Moving a single node just slightly towards the presented sample vector in the fine
tuning will improve the QE of the map (slightly). However, as the input data is
high dimensional, the distances in the vector space Rd are getting more and more
similar due to the "curse of dimensionality", and thus, moving just a single node
can alter the grid structure so that the first and second BMUs for sample vectors
will map to non-distinct nodes (thus increasing the TE) more easily. As the absolute
number of these easily topography breaking iterations increase, the resulting TE for
the map will increase. Thus the optimal value for rlen was set to 700 (based on the
evaluated QE). The decrease rate in the neighbourhood function was later altered,
as this way it was possible to improve the quality of the resulting mapping also in
terms of TE. The optimization was performed as described in section 4.2.2, and the
results of the QE and TE from iterations having different proportion of fine tuning
out of the total number of iteration steps are illustrated in the Figures 6a and 6b.
As can be seen, decreasing the amount of fine tuning at the end of SOM training
have only a minor effect on the QE (expect when totally omitted), but the decrease
is clear in terms of TE from the very beginning. Thus the final decrease in the
neighbourhood function was selected based on the "elbow criterion" so that it will
start as containing 2/3 of the nodes (the default starting value of the kohonen
implementation), and decrease linearly so that only the last 5% of the iteration steps
will be performed as fine tuning (moving a single node at a time), as this way the
trained SOM would also retain the local topology of the input data better.
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Figure 6: Average QE (a) and distance based TE (b) as a function of the num-
ber of training iterations during the neighbourhood function radius decrease rate
optimization
To summarize, the final input data and free parameters of the SOM are as follows:
• Input data features: 79 input variables, one of which was a categorical variable
with 6 levels (converted to 5 dummy binary variables), and another categorical
with 4 levels (converted to 3 dummy binary variables), i.e. 85 features
• Training samples: 1,600 (all patients with both BL and FU data present)
• Test samples: 2,809 (patients with data on single visit)
• Grid topology: dual-layer toroidal hexagonal (expert opinion)
• Grid size: 10× 18 nodes (height × width) (optimized)
• Prototype initialization: random selection among training vectors without
replacement (default)
• Neighbourhood function: radial boundary as described in Equation (4) (default)
• Learning rate: linearly decreasing from 0.05 to 0.01 (default)
• Number of training iterations: 700 × number of training samples, i.e. 1,120,000
rounds (optimized)
• Neighbourhood radius decrease: linear so that initially 2/3 of the nodes belong
to neighbourhood, and only the last 5% of the training is performed as fine
tuning (optimized)
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5.2 Optimal SOM fit and visual evaluation of the approach
After the parameters of the SOM were optimized, multiple (1,000) SOMs were trained
with random initializations in order to find the optimal SOM fit. After the optimal
mapping was selected, the patient data was visualized on the grid plane to allow for
visual evaluation of the mapping performance.
In this work, a multi-layer SOM was selected as a underlying tool to create the
novel patient classes, as we hypothesized that using measures from different time
points in different layers of the SOM could help to capture the progressive nature of
diabetic complications. Based on the visual inspection of input data, the approach
seems to reach this target (see Figure 7). When the variables in the BL layer of
the SOM are illustrated in the node grid (as averages of the mapped patients), it
seems that many of the traits are centered into relatively well restricted regions,
or the border between high and low magnitude nodes is generally visible. When
these variables are illustrated in the FU layer correspondingly, it seems that most of
the variables that have progressive nature (i.e. can "only get worse" almost in all
cases, for example use of medication and diabetic complications themselves) show
phenomenon where the "high risk region" spreads on the grid, but mainly only to
nearby nodes. Thus these "low magnitude nodes" close to "high magnitude nodes" on
BL layer have a special role: the magnitude of the variables are more likely to increase
compared with low magnitude nodes further away, when the BL and FU layers are
compared (see Figure 7 comparing middle and right plots). On the contrary, the
variables that can fluctuate to either directions between the visits (for example BMI,
blood pressure markers and lipid profiles) do not show the same phenomenon, i.e. a
node with intermediate magnitudes near high magnitude nodes does not necessary
imply an increase from the BL to FU layer, as illustrated in Figure 8 (compare middle
and right plots). Thus the SOM seems to be able to map the patients progressing
between the BL and FU visits in terms of a progressive trait to the same map region,
located approximately between the high and low prevalence regions of the BL layer,
which therefore represents patients with a high risk of progression.
Furthermore, it seems that the baseline layer surface is very similar when the
training and testing patients are compared (as illustrated in Figures 7 and 8 between
the left and the middle plots), despite the highly dimensional input data, and possible
small overlearning of the SOM. Thus the patients having their cross-sectional single
time point profiles similar to the training patients, whose complications progressed
between the BL and FU visits, are mapped to the same regions. Therefore these
patients are expected to show complication progression in the near future. This also
supports the assumption that mapping patients to the multi-layer SOM based on a
single layer is meaningful and well motivated.
When the latest outcome variables are visualized (see Figure 9), it seems that
the map also has a predictive value years beyond the FU layer. All three outcome
variables, mortality, macrovascular events, and DN progression, showed notable
structures in the SOM grid, which reflects also the effects of known risk factors for the
complications and mortality. The regions showing the largest mortality are mapped
to the same regions that had patients with the most severe complications (especially
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DN and CVD), widest medication usage, and that were the oldest. Correspondingly,
a high risk for incident macrovascular events was found around regions that contained
patients that had macrovascular events already prior to the BL visit. Finally, the
risk of progression of DN was found in the region with the patients having already
more advanced DN and/or worse glycaemic control (higher blood HbA1c values).
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Figure 7: Distribution of selected variables with a progressive nature in the SOM
layers as averages of patients mapped to each node. For each trait, plots from left to
right represent: BL layer of test patients, BL layer of training patients, and FU layer
of training patients. Nodes having missing data for all of the mapped patients (or
no patients were mapped to them) are coloured black. The colouring scheme across
datasets and layers is harmonized to help interpretation. All illustrated variables
were used as input data for the SOM, except for the number of AHT medication (7d),
which was excluded due to linear dependencies. Other medication related binary
variables used as input variables behave similarly.
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Figure 8: Distribution of selected variables in the SOM layers as averages of patients
mapped to each node. For each trait, plots from left to right represent: BL layer of
test patients, BL layer of training patients, and FU layer of training patients. Nodes
having missing data for all of the mapped patients (or no patients are mapped to
these nodes) are coloured black. The colouring scheme across datasets and layers is
harmonized to help interpretation. All illustrated variables were used as input data
for the SOM, except for the BMI (8a), which was excluded due to known non-linear
dependencies.
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Figure 9: The incidence (estimated annual events per 1000 patients; left) and follow-
up time weighted prevalence (right) of traits since the BL visit estimated from
latest available data. The colour scheme for incidence was square root transformed
to highlight differences on nodes with lower incidence levels, and thus different
colouring was used. New macrovascular events (9b) include all hospitalizations from
cardoiovascular and cerebrovascular events. Only patients without macrovascular
events prior to BL visit were considered, and thus the top right part of the plot,
containing only patients with prior macrovascular events, is left black. For DN
progression, patients with BL ESRD were excluded, as it is considered the most
severe state of DN, and thus cannot progress to worse.
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5.3 Selection of the clustering method
When selecting the optimal method for prototype clustering, in the first step the
most suitable cost function for agglomerative hierarchical clustering was evaluated by
training 100 SOM maps, and clustering the resulting prototypes using agglomerative
hierarchical clustering with different cost functions as described in section 4.3. The
performance of clustering was evaluated using AC, and the results are presented in
Figure 10.
As Figure 10 clearly illustrates, the Ward’s criteria yield the largest AC on
average and the good performance is very robust compared with other cluster merging
criteria. Thus it was selected as the most suitable cost function for agglomerative
hierarchical clustering, and it was next compared with other more sophisticated
clustering methods.
In order to do this, the 1,000 SOMs trained to find the optimal fit were clustered
using the three clustering methods of interest (agglomerative hierarchical clustering
using Ward’s criteria, spectral clustering, and clustering by affinity propagation). The
resulting cluster assignments for each patient were tracked throughout the iteration
steps, and the proportions of robustly classified patients (i.e. patients classified
into the same cluster more often than the current threshold) as a function of the
robustness threshold are presented in Figure 11.
As Figure 11 illustrates, among the three tested clustering methods, spectral
clustering can classify the patients most robustly in case of a two class problem,
whereas Ward’s clustering and clustering by affinity propagation seem to perform
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Figure 10: Box-plot of AC for different cluster merging criteria in agglomerative
hierarchical clustering.
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Figure 11: Proportion of patients robustly assigned to the same class throughout
iterations (left) and closer zoom to higher robustness requirements (>95%, right)
relatively similar. Using spectral clustering, more than 75% of the patients are
assigned to the same cluster at least 95% of the time. The corresponding proportion
for both affinity propagation and Ward’s clustering is 59%. Correspondingly, if the
robustness threshold is increased all the way to 100%, spectral clustering can still
classify approximately 57% of the patients into the same cluster regardless of the
random initialization and by definition random nature of the underlying SOM. The
corresponding proportion for Ward’s clustering is 23%, and only 18% for affinity
propagation.
Next the heritabilities between the robustly classified patient classes were es-
timated for the three clustering methods. The estimates were computed for four
different robustness requirements (80%, 90%, 95% and 99% of the cluster assign-
ments being same). Additionally, the heritabilities were estimated from the two-class
clustering assignments of the optimal SOM mapping. The results of these analyses
are presented in Table 2.
Based on these results, it seems that all the clustering methods can separate
robustly classified patient classes that show significant (p < 0.05) heritability. How-
ever, Ward’s clustering failed to repeat this outcome, when only the most robustly
classified patients (99% of the class assignments same) were used, whereas the heri-
tability of classes resulting from either spectral clustering or affinity propagation still
showed significant heritabilities (p < 0.05, no significance threshold correction). On
the contrary, Ward’s clustering was the only one to create classes with significant
heritability when applied to the optimal fit of the SOM. At the same time, affinity
propagation was the only clustering method that showed increasing point estimates
for heritability when the robustness threshold was increased (and thus more specified
patient groups with genetically divergent background were identified), which is a
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Table 2: Heritability estimates and their statistical significance in patients robustly
classified throughout the SOM iterations, and in the optimal SOM mapping in
two-class clustering problem. h2: Estimated narrow-sense heritability; SE: Standard
error of the heritability estimate; p: p-value for the hypothesis h2 = 0; N : Number
of unrelated individuals used to compute the estimates, pruned with GCTA using
--grm-cutoff 0.025 flag.
Ward’s clustering Spectral clustering Affinity propagation
h2[SE] N p h2[SE] N p h2[SE] N p
80% 0.16 [0.09] 2,845 0.033 0.15 [0.09] 3,063 0.031 0.19 [0.09] 2,820 0.013
90% 0.20 [0.11] 2,498 0.024 0.13 [0.09] 2,879 0.063 0.19 [0.10] 2,521 0.017
95% 0.19 [0.12] 2,213 0.038 0.17 [0.10] 2,754 0.029 0.25 [0.16] 2,222 0.008
R
ob
us
tn
es
s
99% 0.15 [0.14] 1,740 0.136 0.16 [0.10] 2,520 0.046 0.34 [0.17] 1,591 0.020
Optimal fit 0.20 [0.08] 3,384 0.009 0.10 [0.08] 3,384 0.081 0.09 [0.08] 3,384 0.118
desired outcome when even tighter subgroups of patients are formed by increasing
the number of clusters in the next step. Combined with the results of robustness
analysis, where spectral clustering performed best among the methods, the decision
of the most suitable clustering method is not straightforward.
Thus the selection was also based on the default properties of the approaches. As
the affinity propagation implementation of clustering with a predefined number of
clusters is based on iteratively adjusting the initial diagonal elements of the affinity
matrix until the algorithm converges to a desired number of clusters, it can fail in
the task in certain cases. Correspondingly, in the used implementation of spectral
clustering, the final step (i.e. creating the clusters in the spectral subspace) is based
on the k-means algorithm, which causes a small degree of additional randomness
to the resulting clusters. The pilot analyses suggest that with small k the created
clusters are robust, but increasing k above five already causes a random fluctuation
for some nodes close to the cluster borders (data not shown). Thus agglomerative
clustering using Ward’s criteria was selected to be used to create the final phenotype
classes, as the approach does not have additional degree of randomness, and it will
always succeed in the clustering task. In addition, due to its hierarchical nature, it
is possible to visualize the created clusters also by using a dendrogram, which adds
additional insight to the number of clusters in the data. Finally, Ward’s clustering
was the only method to show significant heritability in the optimal SOM mapping,
and the robustness requirements of the two class clustering are not vital for the main
goal of this work, as the phenotypes are created using the optimal SOM mapping.
5.4 Cluster borders and novel phenotype classifications
When the patients were divided into k = {2, 3, ...} classes using Ward’s clustering, at
first the magnitudes of significant heritabilities were increased (both point estimate
for the heritability and its significance) with increasing k. However, increasing k > 4
made the heritability estimates decrease in magnitude and become less significant,
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Figure 12: The dendrogram from Ward’s clustering, cut to create 6 clusters. Clusters
colored according to the mapping presented in Figure 13e
possibly due to the continuously decreasing size of the clusters (causing larger
standard errors (SE), and thus, smaller p-values for the estimates). Still the point
estimates for heritability were surprisingly large for certain pairs of patient groups,
even though the estimates were non-significant after Bonferroni correction. All the
heritability estimates and their significance between pairs of groups for each k are
presented in Appendix B. For group labels regarding the SOM grid positions, refer
to Figure 13. The significant heritabilities between pairs of groups further analysed
in the GWAS setting are highlighted in green (and the results of these analyses are
presented in section 5.6).
The most significant heritability was observed when the patients were divided
into four classes, between groups 1 and 2 (h2 = 42%, p = 1.8× 10−4). The resulting
estimate is approximately of the same magnitude compared with previously reported
heritability estimates of various diabetic complications [8, 72]. When the dendrogram
is cut to create six clusters, an interesting small group of patients can be identified,
which shows large point estimates for heritability when compared with the other
groups created in the same clustering (5 vs. 6: h2 = 69%, p = 0.11; 5 vs. 2:
h2 = 61%, p = 0.039; 5 vs. 1: h2 = 51%, p = 0.041). However, these heritabilities
are non-significant (required Bonferroni corrected p-value for 15 pairings of 6 clusters
p < 0.05/15 = 0.003), and are thus considered as suggestive.
The splitting of the clusters was stopped after k = 6, as the dendrogram, illustrated
in Figure 12, shows that if the cut threshold would be lowered to increase k, next
there would be multiple clusters merged at approximately the same level. Thus
these new clusters are not as clearly separated and there is no motivation to further
increase k. In addition, the heritabilities were mostly non-significant already at
k = 6, and number of patients in additional sub-clusters would continuously become
smaller causing more fluctuation into heritability estimates (and thus more likely
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Figure 13: Created clusters and cluster boundaries visualized in the grid-plane of
the SOM for k = {2, 3, 4, 5, 6}
non-significant estimates). The corresponding cluster borders and assignments for
each k = {2, 3, 4, 5, 6} in the SOM grid-plane are presented in Figure 13.
The resulting clusters are connected in the SOMs’ grid-plane (the sides are
connected as the actual plane was folded to a torus), except for a small disconnected
component of three nodes visible at the top left corner of the plots. Thus the clusters
are somewhat smooth, and intuitively the node prototypes (and therefore the patients
mapped to them) should be relatively similar within each cluster.
5.5 Clinical profiles of the clusters
The following subsections will present the distribution and differences of clinical
variables in in contrast to the created patient classes resulting from cutting the
dendrogram from different resolution levels. For numerical cluster labels, refer back
to Figure 13.
5.5.1 Two clusters: high and low complication risks
When the SOM map was divided into two clusters, the resulting patient division
seemed to follow severe microvascular complications, and high medication usage as
illustrated in Figures 14a to 14c. Thus these classes are further referred as "high risk
cluster" (group 1) and "low risk cluster" (group 2).
The most striking difference was seen in terms of normal AER status, which
almost perfectly follows the cluster assignments (in high risk cluster, 1,306/1,444 had
abnormal AER at BL and in low risk cluster only 221/2,753 had abnormal AER at
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Figure 14: Selection of variables illustrated in the BL layer of the SOM using all
mapped patients. Cluster borders according to assignments k = 2. Of these variables,
the count of different antihypertensive (AHT) medication, BMI and total alcohol
intake were not used as input variables (pruned due to dependencies) and are used
as summarizing visualizations.
BL). Also the macrovascular complications are clearly limited mainly to regions with
albuminuria, but form generally smaller sub-regions (see Figure 16). On the contrary,
many clinical variables, variables related to the treatment of diabetes, lifestyle related
variables, and laboratory measures did not follow the cluster borders (see Figures 14d
to 14i), suggesting that the classification is capturing the interesting complication
component instead of trivial differences (for example the age of the patient). However,
the distribution differences between clusters for most of the input variables were still
statistically significant. Among the 84 input variables, 26 did not show significant
differences between the classes (Bonferroni corrected for all 84 input features tested
for each k, p < 0.05/(84×5) = 1.19×10−4). They included anthropometric measures
(height, weight, and hip width), diabetes treatment related variables (use of tablets in
diabetes treatment, insulin treatment type, insulin dose, and time from diabetes onset
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to initiation of insulin therapy), self-reported lesser complications and medication
variables (use of thyroxin, hormone replacement and rarer types of AHT medication,
self-reported asthma, thyroid disease and rheuma), lifestyle related (weekly beer and
wine dose, and social classes 3 to 5), family complication related (incidence of stroke,
use of AHT medication or prevalence of diabetes in father, incidence of stroke in
mother, count of siblings and prevalence of diabetes in them), serum apolipoprotein
A-I (ApoA-I), and volume of the urine sample. It is worth noting that all the
micro- and macrovascular complications, and variables related to the medication
commonly used to treat them, were highly significantly differentially distributed
among the clusters. Thus the cluster separation could be roughly described as
"patients with multiple severe complications versus patients without them", and
the genetic differences found between these two classes can be assumed to represent
mainly the microvascular (and partly macrovascular) complications, especially DN.
The difference in latest available outcome data was also significant between the
clusters. Mortality in high risk cluster was higher than in low risk cluster (519/1,495
= 35% vs. 138/2,860 = 5%), incident CVD events were more frequent in high risk
cluster than in low risk cluster (468/1,165 = 40% vs. 276/2,819 = 10%), and finally
DN progression was also more common in high risk cluster compared with the low
risk cluster (384/1,023 = 38% vs. 186/2,391 = 8%).
When the variables were inspected regarding their change between the BL and
FU layers, 9 showed a different behaviour between the groups when moved from BL
to FU. These included both SBP and DBP, which became more similar between the
groups; CHD, which increased more rapidly in high risk cluster; beta blockers whose
usage increased more in high risk cluster; ACE inhibitors, whose usage became more
similar (even though there still was a clear difference in FU) between the clusters;
serum apolipoprotein B (ApoB), total cholestrol and blood HbA1c that were lowered
to approximately similar levels in both clusters; and finally serum urate that had a
stronger increase in high risk cluster.
5.5.2 Three clusters: low risk cluster split
When the number of clusters was increased from two to three, the previous low
risk cluster was split into two. The other half, illustrated in the middle of the
plots in Figure 15, seems to contain more strictly defined "control patients" with
lower prevalence of milder degrees of complications and use of medication (Figure
15b) compared with the other half. Therefore the middle cluster (cluster 2) will
further be referred as "(remaining) low risk cluster", and the other half (cluster
3) as "intermediate risk cluster". Among the complications, the difference in the
prevalence of milder levels of DR changes seems to be the most distinguishing between
the created sub-clusters based on the visual inspection (Figure 15c). Furthermore,
patients remaining in low risk cluster seem to have also earlier diabetes onset. At this
cluster division, also surprising variables show differences between the just created
sub-clusters as the count of siblings seems to be higher in the intermediate risk
cluster.
When the variable distributions in different clusters and between layers were
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Figure 15: Selection of variables illustrated in the BL layer of the SOM using all
mapped patients. Cluster borders according to assignments k = 3. Of these variables,
any AHT medication and age at diabetes onset were not used as input variables
(pruned due to dependencies).
further compared using generalized linear modelling, among the 84 input features
only 6 did not show significant differences between the clusters. These variables were
a smaller subset of variables not showing differences in previous group assignments
(k = 2): hip circumference, insulin treatment type, use of rarer AHT medication, use
of warfarin, weekly beer dose and social class 3.
When the changes between the layers were further inspected, the same variables
showing differences in change between layers in k = 2 showed different behaviour
also in the case of k = 3 with a similar interpretation. However in addition to the 9
previously found variables, now also the use of thyroxin, and the prevalence of self
reported thyroid disease show a different behaviour, as the low risk cluster shows
higher increase in the prevalence for both (due to very low BL prevalence).
Based on the heritability results, the most significant genetic differences can
be found between high risk cluster and remaining low risk cluster. Furthermore,
the cluster border between them follows relatively closely the mortality, incident
CVD events, and the DN progression rates derived from the latest available registry
based data (see Figure 9). This is seen also as significant differences in the cluster-
wise prevalence of these traits: all three were more frequent in the high risk cluster
compared with the remaining low risk cluster (mortality 519/1,495 = 35% vs. 24/1,609
= 1%; incident CVD event 468/1,165 = 40% vs. 57/1,602 = 4%; and DN progression
384/1,023 = 38% vs. 114/1,377 = 8%).
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5.5.3 Four clusters: high risk patients with CHD
When k was further increased to create four clusters, a small subgroup of patients
was separated from the high risk cluster of the previous assignments. This group
had a clearly higher prevalence of CHD related traits as illustrated in Figures 16a
to 16c. Thus this small subgroup of high risk cluster will later be referred as "CHD
cluster". However, the separation did not follow all macrovascular complications, as
nodes with a high prevalence of stroke and PVD related traits prior to the BL visit
were still included in the high risk cluster (see Figures 16d to 16f).
The cluster-wise distributions were significantly different between all variables,
except for the same six variables evenly distributed in the case with k = 3. The
set of variables showing significant cluster-layer interaction was almost the same as
in the k = 3 assignment. Splitting of the high risk cluster removed the interaction
with CHD and use of beta blockers, but introduced an interaction in terms of acute
myocardial infarction (AMI), as the new CHD cluster showed a small decrease in
prevalence of AMI from BL to FU data. This decrease can be explained by sampling
bias, as the region is associated with high all cause mortality, and some of the patients
with AMI prior to BL died before FU visit lowering the proportion of patients with
AMI in FU layer.
The heritability between the newly created CHD cluster and other clusters could
not be estimated, as the genetic variance component escaped the parameter space
during the iterative model optimization when the heritability was estimated using
GCTA. However, the remaining high risk cluster (cluster 1) showed the most
significant heritability among any cluster assignment for any k tested, when it was
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Figure 16: Selection of variables illustrated in the BL layer of the SOM using all
mapped patients. Cluster borders according to assignments k = 4.
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compared with low risk cluster (cluster 2). The difference in mortality between these
clusters was slightly smaller than in case k = 3 (high vs. low risk clusters: 389/1,270
= 30% vs. 24/1,609 = 1%). Still, the difference of incident CVD and DN progression
were of the same magnitudes compared with assignment k = 3 (CVD: 451/1,145 =
39% vs. 57/1,602 = 4%; DN progression: 340/901 = 38% vs. 114/1,377 = 8%)
5.5.4 Five clusters: rapid DN progressors among high risk patients
With k = 5, the larger high risk cluster of patients from previous assignments was split
in two, mainly based on the degree of DN, as illustrated in Figure 17. Patients with
microalbuminuria and ESRD were clearly separated into different clusters, however,
the cluster border splits the region containing patients with a high prevalence of
macroalbuminuria. The separation in this region is notable in terms of serum
creatinine and cystatin C, both of which are markers of kidney function (see Figures
17a to 17e). The half with more severe complications is still referred as "(remaining)
high risk cluster", and the separated half is referred as "rapid progressor cluster" due
to the findings of regression modelling (further described later in this section). In
addition, the remaining high risk cluster had a more frequent use of calcium channel
blockers (a type of AHT medication), and yet higher blood pressure values. Finally,
the separation was also seen in terms of additional medication (more common in
high risk cluster), not belonging to the general classes of common medication (see
Appendix A for used classes).
When the distribution of input variables in these classes were further tested,
clearer differences between the clusters emerged, as the smaller subgroups began to
represent more extreme ends of the population spectrum. Among the input variables,
only three (insulin treatment type, other AHT medication, and social class 3) were
still evenly distributed among the created classes, and all the other variables showed
significant differences in distribution. The more specified clusters created showed
also additional differences between the the BL and FU layers as the number of
variables showing significant cluster-layer interaction increased to 19. These variables
contained all the ten variables from the previous cluster assignment (k = 4), and
the additional variables reflect mainly the more rapid progression of DN and related
traits in rapid progressor cluster (cluster 2). Markers of kidney function, serum
creatinine, serum cystatin-C, 24h urine collection albumin-to-creatinine ratio (ACR),
liver fatty acid binding protein to creatinine ratio, and overnight urine AER, all
increased more rapidly in rapid progressor cluster, whereas they stayed approximately
at the same levels or decreased to lower levels in the other clusters. The prevalence
of microalbuminuria, decreased in rapid progressor and CHD clusters (due to DN
progression to worse levels), whereas it increased in other clusters (progression
from normal AER to microalbuminuria, or survival bias in high risk cluster where
some patients with more severe stages of DN deceased between BL and FU visits
making the non-microalbuminuric sample in FU layer smaller, thus increasing the
proportion). Other variables showing interaction included use of calcium channel
blockers, that increased more rapidly in rapid progressor cluster; use of non-steroidal
anti-inflammatory drugs, which became significantly lower in CHD cluster compared
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Figure 17: Selection of variables illustrated in the BL layer of the SOM using all
mapped patients. Cluster borders according to assignments k = 5.
with the rest; and finally, number of cigarettes smoked, which increased more rapidly
in rapid progressor cluster.
In terms of heritability, the point estimates became smaller and less significant,
compared with k = 4. The only significant heritability was observed between the
remaining high risk cluster and the low risk cluster. Still, this suggests that the
genetic differences are most detectable between the extreme ends of complication
spectrum. Splitting the high risk cluster also highlights the difference in outcome
variables by increasing the mortality, DN progression and incident CVD events in
the high risk cluster (mortality: 304/707 = 43%; incident CVD event: 311/593=52%;
DN progression: 194/412=47%).
5.5.5 Six clusters: thyroid disease
In the final cluster division, a small subgroup of patients was separated from the
large intermediate risk cluster. This group had a high prevalences of self-reported
thyroid disease and use of thyroxin medication as illustrated in Figure 18, and is
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Figure 18: Selection of variables illustrated in the BL layer of the SOM using all
mapped patients. Cluster borders according to assignments k = 6.
thus further referred as "thyroid cluster".
The separation of this small group of patients affected the cluster-wise distribution
differences so that use of warfarin was not differentially distributed any more, but
social class 3 became significant compared with k = 5. For the cluster-layer interaction,
almost the same variables as in k = 5 showed significance, with the exception that
the use of non-steroidal anti-inflammatory drugs, and 24h urine sample liver fatty
acid binding protein to creatinine ratio became non-significant again.
The new thyroid cluster separated from the intermediate risk cluster showed
surprisingly large point estimates of heritability between multiple groups, however,
none of which were significant after Bonferroni correction (e.g. groups 2 vs. 5:
h2 = 61%, p = 0.039). Thus it might be possible that the large heritability estimates
reflect the genetic component responsible for thyroid disorders, some of which have
been previously shown to be highly heritable [73, 74].
5.5.6 Summary of the created clusters
To summarize the created clusters, at the lowest resolution level when only two
clusters were created, the cluster assignment could roughly be described as "patients
with multiple complications versus patients without them". When the resolution was
increased and more clusters were created, both the initial high and low risk clusters
were separated into a smaller sub-clusters. From the initial low risk cluster, first
patients with an intermediate complication risk/prevalence were separated, and later,
a special group of patients with high prevalence of thyroid disorders was identified
within the intermediate risk cluster. Correspondingly, within the high risk cluster,
first a group of patients with high CHD prevalence was separated, after which, the
remaining high risk cluster was split into two. One of the halves contained patients
with already severe complications and the other contained patients with mainly
microvascular complications that demonstrated more rapid progression of DN related
traits compared with any of the other clusters. Generally, when the number of
clusters was increased, the number of input variables evenly distributed among the
classes decreased. Correspondingly, increasing the number of clusters introduced
additional cluster-layer interactions for groups. The most significant features of the
created clusters in terms of the clinical phenotypes are summarized in Figure 19.
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Low risk
• Very low complications
• Very low medication
• Very low mortality
CHD
• High CHD
• High mortality
• Varying DN level
• High & severe DR
High risk
• Mainly macro/ESRD
• High & severe DR 
• Stroke/PVD
• High mortality
Intermediate risk
• Mainly normal AER
• Intermediate & mild DR
• Very low CVD
Thyroid
• Very high thyroid disease at BL
• Otherwise similar to 
intermediate risk cluster
Rapid progressor
• Mainly micro/macro
• High & severe DR
• Rapid DN progression
• No/low CVD (at BL)
Figure 19: Summary of the most distinguishing complication profiles of the created
clusters. Abbreviations micro and macro refer to microalbuminuria and macroalbu-
minuria correspondingly. Specifications low/intermediate/high refer to the prevalence
of a complication, and mild/severe to the severity of the complication.
5.6 Genetic components of the novel phenotypes
The following section will present the results of the GWAS analyses between patient
classes showing significant heritabilities, as presented in Appendix B. Each subsection
will present the Manhattan and QQ-plots summarizing the GWAS analysis of the
created phenotype at hand, and will then concentrate on the few top associated
loci, the genes around these regions, and possible previously reported connections to
diabetic complications and related traits.
5.6.1 Two clusters
When the patients were divided into two, in the case of k = 2, the division could be
roughly described as "patients with diabetic complications versus patients without
them", as presented in section 5.5. Already these rough patient classes showed
significant heritability, and were thus analysed in the GWAS setting. The results of
these analyses are summarized in Figure 20.
As the QQ-plot presented in Figure 20b illustrates, there is no inflation of type I
error in the analyses (λQC = 1.01). The associations show some loci with suggestive
p-values (p < 1 × 10−5), the strongest of which on chromosomes 16, 3 and 2 (as
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illustrated in Figure 20a). However, no association reached genome-wide significance
in these analyses (pmin = 1.06× 10−7 > 5× 10−8). The strongest associated SNPs
in the top four loci (lead SNP and two following SNPs) are presented in Table 3,
including their p-values for association and effect sizes.
Even though the associations did not reach genome-wide significance, the topmost
associated loci are located near genes that show biological links to the development
of diabetic complications. First, the region with the most significant association
(rs72803939 on chr16, p = 1.06 × 10−7) is located in the last intron (8/8) of the
WWOX gene. Variants in this same intron have previously been associated with
plasma high-density lipoprotein (HDL) -cholesterol and triglyceride (TG) levels [75].
Interestingly, abnormal lipid profiles are risk factors for both micro- and macrovascular
diabetic complications as presented in section 2.2.
The second strongest association (rs55995864 on chr3, p = 3.14× 10−7) is located
near the HES1 gene (approximately 100kb upstream), which belongs to the Notch
signaling pathway, being a downstream effector of the Notch-1 receptor ligand Jagged1
encoded by JAG1. Upregulation of Notch-1 signaling has been previously associated
with diabetic nephropathy [76], and more importantly, increased levels of Hes1 and
Jagged1 were observed in renal biopsies from patients with DN compared with
biopsies from healthy non-diabetic controls [77]. However, there are also studies
suggesting that genetic markers in genes belonging to the Notch-1 signaling pathway
are not associated with DN [78], and thus the link is under debate.
The third strongest association detected (rs707098 on chr2, p = 1.38× 10−6) is
located approximately 5kb upstream from the GALNT13 gene, which is an enzyme
responsible for the synthesis of O-glycan [79]. Previously, changes in O-glycans have
been reported in renal tissues of alloxan diabetic rats, and other animal studies
(a) Manhattan plot of associations (b) QQ-plot
Figure 20: Manhattan plot (a) and QQ-plot (b) of the GWAS results between high
and low risk clusters of k = 2. In the Manhattan plot, the x-axis is the chromosome
and bp-position of the tested SNP, while the y-axis is the strength of association.
Each of the plotted points represents one of the SNPs tested. In the QQ-plot,
the x-axis is the expected random p-values, and the y-axis represents the observed
p-values of the analysis. Large deviation from the diagonal (throughout all points)
suggests inflation of type I error.
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Table 3: Top loci of GWAS results in the clustering k = 2. A1: Reference allele; A2:
Risk allele, FRQ: Allele frequency of A2; INFO: Imputation quality information
criteria; OR: Multiplier for risk to belong into group with higher complication
prevalence for each copy of A2; SE: Standard error for beta (log[OR])
SNP chr bp A1 A2 FRQ INFO OR SE p-value
rs72803939 16 78,577,080 C G 0.12 0.93 1.53 0.08 1.06× 10−7
rs72801987 16 78,556,270 A G 0.11 0.90 1.53 0.09 8.49× 10−7
rs72803915 16 78,563,954 C T 0.11 0.95 1.51 0.08 1.06× 10−6
rs55995864 3 193,784,165 T A 0.29 0.91 1.35 0.06 3.14× 10−7
rs56280518 3 193,785,348 C A 0.29 0.95 1.34 0.06 4.51× 10−7
rs12487368 3 193,787,775 C T 0.29 0.99 1.33 0.06 5.38× 10−7
rs707098 2 155,318,908 G C 0.52 0.99 1.29 0.05 1.38× 10−6
rs741602 2 155,315,938 C T 0.48 1.00 0.78 0.05 1.46× 10−6
rs10932050 2 155,316,574 C T 0.47 0.99 0.78 0.05 2.42× 10−6
rs62534516 9 14,511,929 T C 0.02 0.81 0.32 0.24 3.48× 10−6
rs62534485 9 14,470,752 G T 0.03 0.91 0.42 0.20 2.00× 10−5
rs62534481 9 14,466,021 A T 0.03 0.92 0.43 0.20 2.49× 10−5
suggest that changes in O-glycans have functional relevance to the pathogenesis of
diabetic complications [80]. In addition, variants in GALNT13 have been suggestively
associated with pediatric BMI [79].
The fourth most significant locus (rs62534516 on chr9, p = 3.48 × 10−6) is
located between the genes ZDHHC21 (approximately 40kb downstream) and NFIB
(approximately 100kb upstream). Of these ZDHHC21 interacts with NOS3 (also
known as eNOS) palmitoylating the enzyme encoded by NOS3, and thus it is related
to nitric oxide (NO) metabolism [81]. NOS3 itself has been previously linked to
DN [82, 83, 30] and to DR [31]. In general, impaired NO metabolism affects blood
pressure through vasodilation, and increases oxidative stress which is a common
denominator of diabetic microvascular complications [29].
5.6.2 Three clusters
When the number of clusters was increased from two to three, the low risk cluster of
previous cluster assignment was split into two, and only the half with lower prevalence
of any complications still showed significant heritability compared with the high risk
cluster. The results of these analyses are presented in Figure 21.
The analyses of these patient clusters yield an almost genome-wide significant
association (pmin = 5.95 × 10−8), but it remains still above the threshold. Corre-
sponding to previous analysis with k = 2, the results show suggestive loci that have
connections to complications and related traits, and the inflation in type I error is
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(a) Manhattan plot of associations (b) QQ-plot
Figure 21: Manhattan plot (a) and QQ-plot (b) of the GWAS results between high
and low risk clusters of k = 3.
still constrained (λQC = 1.02, see Figure 21b). The most significant SNPs for four of
the most significant loci are presented in Table 4.
In these analyses, the most significant association (rs62534516 on chr9, p =
5.95× 10−8) was the same SNP detected as the fourth most significant locus of the
analyses with k = 2, between the genes NFIB and ZDHHC21 , which has a plausible
link to diabetic complications via NO metabolism, vasodilation, and oxidative stress.
The second most significant hit was seen on chr7 (rs79477588, p = 4.03×10−7) in the
first intron (1/33) of the DGKI gene. It belongs to a family of diacylglycerol kinases,
which catalyze the conversion of diacylglycerol (DAG) to phosphatidic acid. DAG is
known to activate the protein kinase C (PKC) pathway [84], which in turn is one of
Table 4: Top loci of GWAS results in the clustering k = 3.
SNP chr bp A1 A2 FRQ INFO OR SE p-value
rs62534516 9 14,511,929 T C 0.02 0.81 0.26 0.25 5.95× 10−8
rs62534485 9 14,470,752 G T 0.03 0.90 0.35 0.21 3.57× 10−7
rs62534481 9 14,466,021 A T 0.03 0.91 0.35 0.21 5.70× 10−7
rs79477588 7 137,468,992 C T 0.04 0.81 0.43 0.16 4.03× 10−7
rs79020676 7 137,486,254 T C 0.05 0.83 0.49 0.15 1.43× 10−6
rs74482009 7 137,480,792 C T 0.10 0.87 0.62 0.10 5.44× 10−6
rs202095311 21 16,368,833 GCAAA G 0.03 0.83 0.35 0.22 1.43× 10−6
rs142323171 21 16,404,339 G A 0.02 0.85 0.32 0.27 2.73× 10−5
rs144965913 21 16,397,200 A G 0.04 0.92 0.51 0.17 5.35× 10−5
rs1079323 16 78,667,846 C T 0.76 0.85 0.72 0.07 4.44× 10−6
rs2550615 16 78,668,315 G C 0.76 0.86 0.72 0.07 5.58× 10−6
rs72803939 16 78,577,080 C G 0.13 0.92 1.48 0.09 1.02× 10−5
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the four known damaging pathways in the development of DR [28]. Furthermore,
the enzyme in rat, corresponding to the one coded by human DGKI, has been shown
to be one of the dominant diacylglycerol kinases in the rat retina [85]. The third
most significant hit (rs202095311 on chr21, p = 1.43× 10−6) is located in the last
intron (3/3) of the NRIP1 gene (also known as RIP140 ), which has been associated
with inflammation, as well as lipid and glucose metabolism in patients with T2D
[86]. The fourth most significant locus (rs1079323, p = 4.44× 10−6) was the same
that was found around the lead association in the previous analyses with k = 2, i.e.
variants in the last intron of WWOX. However, the lead SNP was not the same as
in the previous analyses.
5.6.3 Four clusters
When the number of clusters was further increased to k = 4, a small subgroup of
nodes was separated from the previous high risk cluster. The patients in this small
subgroup showed a high prevalence of CHD and related traits, however, the only
significant heritabilities were observed between the remaining high risk cluster and
the previous low risk cluster. This estimated heritability was most significant among
the created classes for any k. Results of the GWAS analysis using this phenotype
are presented in Figure 22.
In the analysis, one genome-wide significant association was detected (rs202095311,
p = 3.81 × 10−8). In addition, the analysis results show also other suggestive
associations. However, the QQ-plot suggests that in general the detected p-values of
associations start to fall below the diagonal, suggesting that the number of patients is
starting to become too small for the GWAS analyses. Still the topmost associations
rise above this trend, and reach smaller (more significant) p-values than in the
previous analysis with k = 3. These and other top most significantly associated loci
are presented in Table 5.
The top association reaching a genome-wide significance (p = 3.81 × 10−8)
was located in a locus associated also in previous analyses (k = 3), in the last
(a) Manhattan plot of associations (b) QQ-plot
Figure 22: Manhattan plot (a) and QQ-plot (b) of the GWAS results between high
and low risk clusters of k = 4.
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Table 5: Top loci of GWAS results in the clustering k = 4.
SNP chr bp A1 A2 FRQ INFO OR SE p-value
rs202095311 21 16,368,833 GCAAA G 0.03 0.83 0.24 0.26 3.81× 10−8
rs142323171 21 16,404,339 G A 0.02 0.84 0.20 0.33 2.17× 10−6
rs182526753 21 16,334,615 T C 0.01 0.98 0.21 0.35 5.45× 10−6
rs62534516 9 14,511,929 T C 0.02 0.81 0.26 0.27 3.48× 10−7
rs62534485 9 14,470,752 G T 0.03 0.90 0.36 0.22 2.68× 10−6
rs75697152 9 14,533,977 G A 0.02 0.81 0.27 0.28 3.95× 10−6
rs10111377 8 104,121,210 A G 0.38 0.91 1.35 0.06 2.33× 10−6
rs13261053 8 104,107,265 C T 0.30 0.94 1.34 0.07 7.78× 10−6
rs6468859 8 104,120,370 G C 0.29 0.93 1.34 0.07 9.96× 10−6
rs75669230 5 158,229,364 T C 0.05 1.00 0.48 0.16 2.69× 10−6
rs12657410 5 158,204,347 A G 0.05 1.02 0.49 0.15 2.89× 10−6
rs12651861 5 158,238,388 T C 0.04 0.96 0.48 0.16 5.65× 10−6
intron of NRIP1 gene (rs202095311, chr21), which has a link to metabolism and
inflammation. The second most significant association (p = 3.48×10−7) was also seen
in both of the previous analyses (k = {2, 3}): it was located in the region between
the genes ZDHHC21 and NFIB (the same SNP rs62534516 that was leading the
association in previous analyses). The third most significant association (rs10111377,
p = 2.33×10−6) was seen on chr8 between the genes ATP6V1C1 (approximately 35kb
downstream) and BAALC (approximately 30kb upstream). Of these, ATP6V1C1
encodes a component of the multisubunit enzyme, vacuolar ATPase (V-ATPase),
which is involved in ROS production in response to bacteria [87]. Generally, increased
ROS production has been hypothesised to be the unifying mechanism of the diabetic
microvascular complications [29]. In addition, Gene Ontology terms link ATP6V1C1
itself to the large insulin receptor signaling pathway (GO:0008286). The fourth most
significant association (rs75669230 on chr5, p = 2.69 × 10−6) was located in the
middle of the EBF1 gene, in intron 8/15. The gene has been previously associated
with metabolic and cardiovascular risk [88, 89] and ebf1 knock-out mice have shown
renal defects [90].
5.6.4 Five clusters
During the next cluster division, when k was increased to five, the previous high risk
cluster was split into two, roughly separating patients rapid DN progression from
the high risk cluster. The heritability between the remaining extreme cases (high
risk cluster) and the previous control group was still significant, even though both
the point estimate and significance were smaller than in the case k = 4, possibly due
to a continuously decreasing number of patients. The GWAS results between these
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classes are summarized in Figure 23.
As the QQ-plot in Figure 23b illustrates, the resulting p-values are falling below
the diagonal, i.e. they are generally worse than expected by random. As all the
performed tests are not independent (due to the LD structure between the SNPs) this
does not imply that the association results would be useless, but suggests that the
number of patients is already too small to detect the underlying genetic associations,
if present. In these analyses the lead associations were almost two magnitudes
larger (worse) compared with the lead associations from k = 3 or k = 4. Still the
most significant regions from this analysis show interesting genetic regions, and are
presented in Table 6.
The most significant hit was seen on chr10 (rs1578671, p = 1.28 × 10−6) on
top of the PCDH15 gene (intron 4/34). Nonsynonymous variants in this gene
have been previously linked to lipid abnormalities (especially TG, ApoB and total
cholesterol levels) [91], and also a common variant in the region has been reported to
be suggestively associated with lipid profiles [92]. The second most significant locus
was found on chr5 (rs200163200, p = 1.42×10−6), around a region where there are no
known genes within a distance of more than 500kb in either direction of the lead SNP.
The third region is found on chr20 on top of gene ABHD12 (intron 4/12, rs35288907,
p = 2.25× 10−6). The encoded enzyme catalyses the hydrolysis of 2-arachidonoyl
glycerol (2-AG), one of the two most important endocannabinoids. Levels of 2-AG
have been reported to correlate with body fat, visceral fat mass, fasting plasma
insulin, and glucose infusion rate during a glucose clamp [93]. Furthermore, the
endocannabinoid system has been shown to generally have complex effects on the
bodyweight and metabolic regulation in general, possibly leading to accumulation
of energy as fat, and thus, it is linked also to T2D [94]. More importantly, the
endocannabinoid system is hypothesised to play a role also in the progression of DR
[95]. Finally, the fourth region was the one detected previously with genome-wide
significant p-value with k = 4: locus on top of the NRIP1 gene on chr21 (rs202095311,
p = 4.47 × 10−6). However, with k = 5, the p-values are two magnitudes smaller
compared with the previous analyses, and no other SNPs in this region around the
(a) Manhattan plot of associations (b) QQ-plot
Figure 23: Manhattan plot (a) and QQ-plot (b) of the GWAS results between high
and low risk clusters of k = 5.
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Table 6: Top loci of GWAS results in the clustering k = 5
SNP chr bp A1 A2 FRQ INFO OR SE p-value
rs1578671 10 56,216,271 C T 0.14 0.96 1.60 0.10 1.28× 10−6
rs11004315 10 56,215,605 G T 0.14 0.97 1.59 0.10 1.72× 10−6
rs3070712 10 56,214,186 CATT C 0.13 1.00 1.58 0.10 4.55× 10−6
rs200163200 5 84,677,581 G GA 0.03 0.91 2.73 0.21 1.42× 10−6
rs188674266 5 84,764,920 G T 0.03 0.91 2.59 0.20 3.17× 10−6
rs190418551 5 85,060,481 G A 0.03 0.96 2.36 0.19 8.41× 10−6
rs35288907 20 25,299,299 CT C 0.60 0.84 0.69 0.08 2.25× 10−6
rs5841058 20 25,433,447 C CT 0.41 0.80 1.45 0.08 3.45× 10−6
rs1044573 20 25,206,654 A G 0.51 1.00 1.37 0.07 9.11× 10−6
rs202095311 21 16,368,833 GCAAA G 0.03 0.83 0.18 0.37 4.47× 10−6
lead SNP reached even nominal p-values (p < 1× 10−4).
For the next clustering (k = 6) the cluster division did not affect the high and
low risk clusters showing significant heritability with k = 5. These same groups were
the only pairing showing significant heritability in the case k = 6, and thus it was
not re-analysed. As previously noted, the dendrogram of Ward’s clustering and the
continuously decreasing heritability estimates suggested that no further increase in k
should be done after k = 6. Furthermore, already using the larger clusters of k = 5
clustering suggested that the resulting number of patients is getting too small for
the GWAS analyses. Thus no further GWAS analyses were performed.
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6 Discussion and conclusions
The primary goals of this work were to use machine learning approaches to subdivide
patients with T1D into novel phenotype classes (based on multiple clinical and
environmental variables), that would simultaneously capture the risk for multiple
diabetic complications; to evaluate whether the resulting class assignments show
genetically differing profiles; and to pinpoint the exact genetic markers associated
with these novel group assignments.
It has been previously shown that SOM-based approaches can map the patients
with T1D successfully by their cross-sectional complication profile and mortality,
using their biochemical profiles as an input [67, 96], which has greatly inspired this
work. Here the traditional SOM was extended to a multi-layer approach, as we
hypothesised that this approach could also capture the progressive nature of the
diabetic complications more efficiently. In this work, a dual-layer SOM was trained
using data from thousands of patients in the FinnDiane study, measured at the
baseline visit (BL) when the patients entered the study, and during a follow-up
visits (FU) years later. After the SOM was trained, the resulting node prototypes
of the SOM were clustered using Ward’s agglomerative hierarchical clustering in
order to create the phenotype classes. These classes were further evaluated for their
intergroup heritabilities, and pairs of classes showing genetically divergent profiles
were used as case-control phenotypes in the GWAS setting.
The created phenotype classes showed meaningful class assignments, as multiple
diabetic complications and their risk factors were differentially distributed between
them. The approach seem to be able also to capture the progressive nature of the
complications, as some of the classes showed more rapid progression of DN and
other complication related variables between the BL and FU layers of the SOM.
Among the complications, abnormal AER of the patients, rate of DN progression and
biomarkers of DN showed the most notable differences between the created classes.
However, this phenomenon might be slightly biased, as the FinnDiane study has a
special emphasis on the study of DN, and thus the data might be partly enriched for
variables reflecting the status and progression of DN. Still, also other complications
showed clustering in the SOM, and some of the created phenotype classes followed
these patterns well. Furthermore, the borders created to separate the different patient
classes followed the mortality and complication progression patterns of the latest
available data, and thus SOM and the created phenotype classes seem to have a
predictive value also beyond the time points of the input data.
The created patient classes also showed differing genetic profiles for multiple pairs
of groups created with different "resolution levels" of the hierarchical clustering, as
evaluated by narrow-sense heritability estimates. The most significant estimates
suggested that certain class assignments could be up to 42% genetically determined.
For some special groups the point estimates for heritability were even larger, but
non-significant possibly due to the small patient samples assigned to these groups.
The pairs of groups showing significant heritability estimates were analysed in the
GWAS setting, where the class assignment was used as a case-control phenotype.
In the GWAS analyses, the group pairing showing the most significant heritability
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highlighted a genetic marker (rs202095311, chr21) in the last intron of the NRIP1 gene
associated with the class assignment with genome-wide significance (p < 5× 10−8).
The gene has previously been associated with inflammation, lipid metabolism, and
glucose metabolism in patients with T2D, and thus it has a biologically plausible
link also to diabetic complications in T1D. The association was achieved with only
2,439 patients included in the GWAS analysis, whereas previous GWAS analyses on
diabetic complications have required more than ten thousand patients to achieve
genome-wide significance [10]. In addition, the analyses of this work highlighted
multiple other regions that showed suggestive p-values (p < 1 × 10−5) for genetic
association around genetic regions and genes previously associated with diabetic
complications, related risk factors and/or relevant pathways, further supporting the
power of the approach.
In addition to a genome-wide significant p-value, replication in an independent
cohort is often required for the genetic associations from the GWAS approach before
they are widely accepted. However, replicating the results of this work is very
challenging, as the data in the FinnDiane study used to train the SOMs is unique in
its comprehensiveness and variety, and thus there are no other cohorts with matching
data that could be used as replication cohorts. However, if such a cohort would exist,
it would be relatively straightforward to map the patients into the optimal SOM
trained, assign them to clusters, and perform the corresponding GWAS analyses.
Still, interpreting the GWAS results in this approach is generally harder compared
with traditional phenotypes, as the class assignments associated with the genetic
markers are created using a wide spectrum of different variables. Thus, it is possible
that the observed association(s) reflect only one of the components having differences
between the phenotype classes. Still, based on the associated loci, genes in nearby
regions, and the traits they have been previously associated with, this is unlikely
the case. However, drawing any final conclusions is still challenging, and thus, the
genetic associations of this work are best suited for future hypothesis generation.
They could be later used for example in pathway enrichment analyses to capture the
wider spectrum of the pathogenesis of diabetic complications, however, this is out of
the scope of this thesis.
To summarize, the selected approach was able to create meaningful patient classes
that showed genetically divergent backgrounds. A genetic variant associated with the
class assignment could be identified, and it and the additional suggestively associated
loci had mostly previously known biologically plausible links to diabetic complications
and/or related traits. Thus the work reached all the primary goals set for it.
The secondary goals of this work were to evaluate the used methodology: whether
the multi-layer SOM approach could capture the progressive nature of the com-
plications, which of the clustering methods would be most suitable to create the
phenotype classes, and finally, whether a corresponding approach could be used also
in other complex traits and diseases.
In this work, clustering of the multi-layer SOM prototypes was selected as the tool
to create the novel phenotype classes. Still, machine learning and data mining are
broad fields and there exist multiple approaches to group data and create classifiers
in order to achieve the same goal of creating novel phenotype classes of patients.
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Selecting SOM as the core tool limits the spectrum of available approaches, and
among the available tools, SOM indeed is a "black box" approach that does not
yield specific classification rules. However, using it does not require complex models
that require pre-assumptions of the data. As SOM has been previously shown to be
a good tool to map patients with T1D, and as the traditional SOM approach had
room for extension into a multi-layer approach that was hypothesised to be able to
capture the progressive nature of the diabetic complications, it was selected to be
used in this work.
As the SOM prototype nodes to be clustered have coordinates in multiple vector
spaces simultaneously, most of the clustering tools are not directly suited for the
clustering task. Many of them could be hand tailored to work on such data, but
creating new implementations of clustering approaches for a specific task was out
of the scope of this work. Thus, the selection of tools was limited to existing,
well documented R implementations of methods that can perform the clustering
based on a (dis)similarity matrix alone. The selection for the most suited tool to
create the phenotype classes was not straightforward. All of the tested methods
had certain features where they outperformed the others, and the final selection had
to be based on the core properties of the used implementations. Still, the results
suggest that having the multi-layer SOM as an abstraction level of the raw data
can make even very simple clustering methods perform well, and it is not necessary
to increase the complexity of the approach by applying more complex clustering
methods. The selected method, agglomerative hierarchical clustering using Ward’s
criteria, is still only suboptimal, and if the corresponding pipeline is applied in other
complex traits and diseases, the selection of clustering method should be given an
additional emphasis. However, the preliminary results suggest that the selection of
clustering method does not have major effects on the final results (see Appendix C).
Regardless of the limited selection of tested methods, the multi-layer SOM based
approach was shown to perform well, and seems to capture the progressive nature of
the diabetic complications. The results of this work look generally very interesting
and can be considered as "a proof of concept". Thus, a similar approaches could be
helpful in hypothesis generation, and for the detection of novel genetic variants and
pathways associated with other complex diseases with multiple sub-phenotypes.
If one wishes to apply a corresponding approach to other complex diseases and
traits, the replication issues of GWAS analyses should also be further considered.
Thus, it would be recommended to select the variables used to train the SOM and map
the patients so that corresponding measures would exist in the possible replication
cohorts. Alternatively, if the initial cohort is large enough (possibly even tens to
hundreds of thousands of patients), separating an independent replication cohort
large enough for a GWAS could be considered.
In this work, the dual-layer SOM design was used due to the structure of available
data, but including additional layers should in principle improve the mapping of the
patients. All of the methods used in this work scale also to additional layers of the
SOM, which could be included if the data is sufficient. Thus applying the approach
to other complex traits with possibly larger patient cohorts, possibly stronger genetic
effects compared with diabetic complications, and possibly longer and tighter follow-
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up data to fill additional layers could show an even better performance compared
with the results of this work.
In conclusion, using multi-layer SOM to create novel phenotype classes could
help the hypothesis generation in complex diseases with a progressive nature. The
approach can highlight the baseline and progression differences of multiple variables
between the created patient classes, and thus, give an additional insight into the
pathogenesis of the disease. The classes can be further tested for a genetically
divergent background to confirm the presence of a genetic effects, and ultimately, the
exact genetic markers, genes and/or pathways associated with the group assignments
can be pinpointed using the GWAS setting.
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A Full list of the SOM input variables
This appendix contains complete list of the input variables used to train the SOMs
in the analyses of this work, including short summaries of the variables and their
data types. Only the 79 variables passing the missingness threshold pruning (further
described in sections 4.1.1 and 5.1) are presented.
Table A1: All input variables included in the training of the SOMs in this work.
Variable Non-
missing
Variable
type
Description
DNGROUP 0.96 categorical
(4 levels)
Nephropathy class [normal
AER, microalbuminuria,
macroalbuminuria, ESRD]
AGE 1.00 continuous Age [years]
DURATION 1.00 continuous Duration of the diabetes [years]
HEIGHT 0.99 continuous Height [cm]
WEIGHT 0.99 continuous Weight [kg]
WAIST 0.97 continuous Waist circumference [cm]
HIP 0.97 continuous Hip circumference [cm]
SBP 0.99 continuous Systolic blood pressure [mmHg]
DBP 0.99 continuous Diastolic blood pressure
[mmHg]
OHATREAT 1.00 binary Diabetes treated with tablets
[y/n]
ANYRETIN 0.97 binary Any retinal changes [y/n]
LASER 0.99 binary Eyes laser treated [y/n]
CHD 1.00 binary Coronary heart disease [y/n]
AMI 1.00 binary Acute myocardial infarction
[y/n]
CORBYPASS 1.00 binary Coronary bypass [y/n]
STROKE 1.00 binary Stroke [y/n]
AMPUTATION 1.00 binary Toe/foot amputation [y/n]
PVDBYPASS 1.00 binary Peripheral vein bypass (foot)
[y/n]
INSTREAT 0.99 binary Insulin therapy type
[injection/pump]
INSDOSE 1.00 continuous Daily insulin dosage [IU]
ANYMED 1.00 binary Any medication [y/n]
Continued on next page
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Continued from previous page
Variable Non-
missing
Variable
type
Description
ACEINHIBIT 0.99 binary Use of ACE inhibitor
(medication) [y/n]
AT2RBLOCK 0.99 binary Use of anginotensin II receptor
blocker (medication) [y/n]
BETABLOCK 0.99 binary Use of betablocker (medication)
[y/n]
CABLOCK 0.99 binary Use of calcium channel blocker
(medication) [y/n]
DIURETICS 0.99 binary Use of diuretics (medication)
[y/n]
OTHERAHTMED 0.99 binary Use of other antihypertensive
medication [y/n]
NITRO 0.99 binary Use of isosorbid mononitrate
(long acting) medication [y/n]
NSAID 0.99 binary Use of non-steroidal
anti-inflammatory drug
(medication) [y/n]
LIPIDLOWMED 0.99 binary Use of lipid lowering medication
[y/n]
THYROXIN 0.99 binary Use of use of thyroxin
(medication) [y/n]
HORMONES 0.99 binary Use of hormone replacement
therapy [y/n]
PPILLS 0.99 binary Use of P-pills (medication)
[y/n]
WARFARIN 0.99 binary Use of warfarin (medication)
[y/n]
OTHERMED 0.99 binary Any other medication not
mentioned before [y/n]
ONSET-TO-INS 1.00 discrete Time from diabetes diagnosis to
insulin treatment [years]
ASTHMA 0.91 binary Self-reported asthma [y/n]
THYROIDDIS 0.91 binary Self-reported thyroid disease
[y/n]
RHEUMA 0.91 binary Self-reported rheumatoid
arthritis [y/n]
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Variable Non-
missing
Variable
type
Description
BEERDOSE 0.83 continuous Self-reported beer consumed
per week [bottles 1/3 l]
WINEDOSE 0.78 continuous Self-reported wine consumed
per week [glasses]
BOOZEDOSE 0.76 continuous Self-reported spirits consumed
per week [dl]
SOCIALCLASS 0.84 categorical
(6 levels)
Self-reported profession
[working personel without
professional education, trained
working personel, lower level
employee, higher level employee,
farmer, not classified]
MOTBIRTHYEAR 0.86 discrete Self-reported birth year of
mother [year]
MOTALIVE 0.95 binary Self-reported mother alive [y/n]
MOTAHT 0.81 binary Self-reported mother has/had
antihypertensive medication
[y/n]
MOTAMI 0.81 binary Self-reported mother has/had
acute myocardial infarction
[y/n]
MOTSTROKE 0.81 binary Self-reported mother has/had
stroke [y/n]
FATBIRTHYEAR 0.84 discrete Self-reported birth year of
father [year]
FATALIVE 0.94 binary Self-reported father alive [y/n]
FATAHT 0.74 binary Self-reported father has/had
antihypertensive medication
[y/n]
FATAMI 0.76 binary Self-reported father has/had
acute myocardial infarction
[y/n]
FATSTROKE 0.75 binary Self-reported father has/had
stroke [y/n]
SIBLINGCOUNT 0.90 discrete Self-reported number of siblings
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Variable Non-
missing
Variable
type
Description
TOTAL-SMOKES 0.92 continuous Self-reported total smokes
(derived from self-reported daily
smoking amount and smoking
periods)
NEVER-EVER-
SMOKED
0.92 binary Self-reported has ever smoked
[y/n]
SIBLING-DM 0.97 binary Self-reported any sibling has
diabetes [y/n]
MOT-DM 0.90 binary Self-reported mother had
diabetes [y/n]
FAT-DM 0.86 binary Self-reported father had
diabetes [y/n]
S-APOA1 0.92 continuous Serum apolipoprotein A-I
[mg/dl]
S-APOB 0.92 continuous Serum apolipoprotein B-100
[mg/dl]
S-CHOL 0.99 continuous Serum total cholesterol
[mmol/l]
S-HDLC 0.99 continuous Serum HDL cholesterol
[mmol/l]
S-HDL2C 0.96 continuous Serum HDL2 cholesterol
[mmol/l]
S-TG 0.99 continuous Serum triglycerides [mmol/l]
B-HBA1C 0.98 continuous Blood haemoglobin A1c
[mmol/mol]
S-CREAT 0.99 continuous Serum creatinine [µmol/l]
S-CYSTATINC 0.86 continuous Serum cystatin C [mg/l]
S-HSCRP 0.95 continuous Serum high sensitive C-reactive
protein [mg/l]
S-SRAGE 0.90 continuous Serum soluble receptor for AGE
[pg/ml]
S-URATE 0.85 continuous Serum urate [µmol/l]
DU-TIME 0.78 continuous 24h urine collection time [min]
DU-VOLUME 0.78 continuous 24h urine volume [ml]
DU-CREAT 0.74 continuous 24h urine creatinine
concentration [mmol/l]
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Variable Non-
missing
Variable
type
Description
DU-ACR 0.72 continuous 24h urine albumin to creatinine
ratio [mg/mmol]
NU-AER 0.55 continuous Night urine albumin excretion
rate [µg/l]
DU-ADIPONCT-
CREA-RTIO
0.55 continuous 24h urine adiponectin to
creatinine ratio
DU-KIM1-CREA-
RTIO
0.64 continuous 24h urine KIM-1 (T
cell-immunoglobulin-mucin-1)
to creatinine ratio
DU-LFABP-CREA-
RTIO
0.51 continuous 24h urine LFABP (liver fatty
acid binding protein) to
creatinine ratio
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B Heritability estimates between defined phenotype
classes
This appendix presents the estimated intergroup heritabilities between the patient
classes, created by clustering the node prototypes of the optimal SOM fit into different
number of clusters (k = {3, 4, 5, 6}) using agglomerative hierarchical clustering and
the Ward’s criteria for the cluster merging.
For some of the class pairs, the genetic variance component escaped from the
parameter space during the iterative model optimization of GCTA run, and thus,
heritability could not be estimated. In these cases, ∗ is presented in the following
tables. Pairs of classes showing significant heritability (Bonferroni corrected for the
number of pairings for current k, i.e. reaching p < 0.05/[12k(k − 1)]) are highlighted
in green, and these pairs were further used as a case-control phenotype in the GWAS
setting. For class labels for each k in contrast to the SOM grid position and the
hierarchical cluster structure, refer to Figures 12 and 13 in section 5.4.
Table B1: k = 3
1 2
h2 [SE] 0.29 [0.11] -
p 0.0048 -2
N 2600 -
h2 [SE] 0.18 [0.12] 0.07 [0.11]
p 0.063 0.223
N 2267 2380
Table B2: k = 4
1 2 3
h2 [SE] 0.42 [0.12] - -
p 1.8× 10−4 - -2
N 2439 - -
h2 [SE] 0.22 [0.13] 0.08 [0.11] -
p 0.058 0.23 -3
N 2113 2380 -
h2 [SE] ∗ ∗ ∗
p ∗ ∗ ∗4
N 1350 1636 1315
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Table B3: k = 5
1 2 3 4
h2 [SE] 0.03 [0.21] - - -
p 0.43 - - -2
N 1165 - - -
h2 [SE] 0.37 [0.13] 0.14 [0.14] - -
p 0.0010 0.17 - -3
N 2017 1904 - -
h2 [SE] 0.36 [0.16] ∗ 0.08 [0.11] -
p 0.01 ∗ 0.23 -4
N 1690 1590 2380 -
h2 [SE] ∗ 0.06 [0.34] ∗ ∗
p ∗ 0.43 ∗ ∗5
N 876 750 1636 1315
Table B4: k = 6
1 2 3 4 5
h2 [SE] 0.03 [0.21] - - - -
p 0.43 - - - -2
N 1165 - - - -
h2 [SE] 0.37 [0.13] 0.14 [0.14] - - -
p 0.0010 0.16 - - -3
N 2017 1904 - - -
h2 [SE] 0.36 [0.16] ∗ ∗ - -
p 0.023 ∗ ∗ - -4
N 1543 1437 2253 - -
h2 [SE] 0.51 [0.31] 0.61 [0.36] 0.23 [0.16] 0.26 [0.23] -
p 0.041 0.039 0.057 0.12 -5
N 842 715 1605 1133 -
h2 [SE] ∗ 0.06 [0.34] ∗ ∗ 0.69 [0.61]
p ∗ 0.43 ∗ ∗ 0.116
N 876 750 1636 1162 407
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C Abstract for EDNSG annual meeting 2016
This appendix contains an abstract of the preliminary results of this work. It was
submitted to the 29th Annual General Meeting of the European Diabetic Nephropahty
Study Group (EDNSG; Palazzo Blu, Pisa, Italy, 20th to 21st of May, 2016) and
accepted to be presented as an oral presentation.
At the time, spectral clustering was used to create the phenotype classes, but
these initial results of class-wise progression of DN and most significant heritability
estimates correspond closely to the final results presented in this work, suggesting
that the selected clustering method does not have major effects on the general results.
GWAS analyses of the classes were not yet performed at the time when the abstract
was written.
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Identifying novel phenotype profiles of patients with T1D using machine learning 
approaches 
Iiro Toppila1-3, Niina Sandholm1-3, Carol Forsblom1-3 and Per-Henrik Groop1-4 on behalf of the 
FinnDiane Study group 
1Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland, 2Abdominal Center 
Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 3Diabetes and 
Obesity Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland, 4 Baker 
IDI Heart and Diabetes Institute, Melbourne, Australia 
Objective: Many diabetic complications correlate with multiple biological markers and each other, 
and this interplay might limit traditional analyses studying one trait at a time. Therefore, the aim 
was to create novel classes of patients with Type 1 diabetes (T1D) considering multiple traits 
simultaneously by using a multi-layer self-organizing map (SOM) and clustering methods, to 
estimate inter-group heritabilities of the created patient classes, and to characterize their profiles. 
Design: A nationally representative prospective cohort study. 
Setting and patients: The study includes 4,409 patients with T1D (insulin initiated within one year 
of diagnosis, age at diabetes onset < 40 years) from the FinnDiane Study, of which 1,600 were used 
to train the SOMs. We used 79 different cross-sectional measures of clinical variables or 
complications from two different time points (corresponding to the SOM layers) to train 1,000 dual-
layer SOMs with random initialization. The optimal SOM mapping was selected, and its node 
prototypes were clustered using spectral clustering varying the number of clusters. The heritability 
between each pair of the created groups was evaluated by the GCTA-software using data from 
genome-wide genotyping (Illumina Human Core+ExomeChip). 
Main Outcome Measurements: Narrow-sense inter-group heritability (GCTA), and the differences 
in the progression rate of DN and input-data profiles between defined patient groups (continuous 
variables tested using Welch two sample t-test and binary variables using Fischer’s exact test).  
Results: The most significant heritability between two of the created classes was observed when all 
4,409 subjects were mapped to the optimal SOM divided into 5 clusters. The difference in DN 
progression was significant (high risk group: 320/714=44.8%; low risk group: 66/957=6.8%; patients 
with baseline ESRD excluded; p<2.2×10-16) between these groups during a median follow-up of 7.2 
years (IQR: 4.8-11.0). The patients in the high risk group showed worse profiles for most of the input 
variables including age, diabetes duration, anthropometric measures, blood pressure, medication, 
severity of baseline complications (DN, retinopathy, cardiovascular disease), familial history of CVD, 
and common blood and urinary markers. However, there were no differences in gender, insulin dose 
and treatment type (injection vs. pump), beer and wine doses, or occurrence of diabetes in father 
or siblings. Heritability (i.e. proportion of phenotypic variance explained by genetic factors) between 
the high and low risk groups was 43% (p=9.13×10-4). 
Conclusions: Multilayer SOM can capture the progressive nature of DN, and create novel phenotypic 
profiles showing different progression rates and divergent genetic background.  
